

Approved



Cote d'Ivoire
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		335,541		335,541	79,389	414,930
USAID		20,624,398		20,624,398	30,954,398	51,578,796
DOD		2,664,412		2,664,412	823,730	3,488,142
HHS/CDC	1,775,000	83,101,733		84,876,733	0	84,876,733
HHS/HRSA		150,000		150,000	0	150,000
Total	1,775,000	106,876,084	0	108,651,084	31,857,517	140,508,601

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						Total
	State	DOD	HHS/CDC	HHS/HRSA	State/SGAC	USAID	
CIRC		0	0	0		0	0
HBHC		301,114	4,558,014	41,250	0	2,013,665	6,914,043
HKID		0	11,626,907	0		4,961,351	16,588,258
HLAB		100,015	1,894,986	0		0	1,995,001
HMBL		0	0	0		0	0
HMIN		0	0	0		0	0
HTXD		0	0	0		202,449	202,449
HTXS	6,107	1,039,748	32,774,540	77,250		2,778,125	36,675,770
HVAB		0	1,212,217	0		828,278	2,040,495
HVCT	6,107	494,429	6,694,970	5,250		3,995,667	11,196,423
HVMS	323,327	0	7,548,999			200,333	8,072,659
HVOP		191,537	2,191,841	0		1,508,826	3,892,204
HVSI	0	268,704	2,492,194	0		260,840	3,021,738

Approved



HVTB		0	5,209,244	7,500		81,950	5,298,694
IDUP		0	0	0		0	0
MTCT		57,902	2,754,018	0		79,668	2,891,588
OHSS		37,947	500,506	0		709,550	1,248,003
PDCS		86,508	2,440,472	15,000		2,366,984	4,908,964
PDTX		86,508	2,977,825	3,750		636,712	3,704,795
	335,541	2,664,412	84,876,733	150,000	0	20,624,398	108,651,084



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	6,237,254
HKID	16,436,739
HVTB	5,237,375
PDCS	4,754,432
Total Technical Area Planned Funding:	32,665,800

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	1,352,346
HVSI	2,403,068
OHSS	1,168,511
Total Technical Area Planned Funding:	4,923,925

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	0
HMBL	0
HMIN	0
HVAB	2,030,685
HVCT	10,838,317
HVOP	3,840,856
IDUP	0
MTCT	2,827,816
Total Technical Area Planned Funding:	19,537,674

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	0
HTXS	34,695,294
PDTX	3,443,544
Total Technical Area Planned Funding:	38,138,838

Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	94 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	627,892
	Number of new ANC and L&D clients	665,939
	By Age (Denominator): 10-14	1,950
	By Age (Denominator): <15-19	97,642
	By Age (Denominator): 20-24	168,697
	By Age (Denominator): 50+	695
	By Number of known positives: 15-19	117
	By Number of known positives: 20-24	813
	By Number of known positives: 50+	12
	By Number of new positives: 10-14	1
	By Number of new positives: 15-19	398
	By Number of new positives: 20-24	1,469
	By Number of new negative: 10-14	1,967
	By Number of new negative: 15-19	92,018
	By Number of new negative: 20-24	157,609
	By Number of new negative: 50+	632
	By Age (Numerator): 10-14	1,977
By Age (Numerator): 15-19	92,234	



	By Age (Numerator): 20-24	158,594
	By Age (Numerator): 50+	683
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	178,702
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	119,564
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	74,903
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	23,786
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	2,228
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	161,211
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	2,357
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	2,386
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	108,810
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	1,869
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	1,581
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	68,945



	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	1,047
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	430
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	21,776
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	214
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	168,048
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	112,666
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	71,300
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	22,391
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	14,599
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	627,892
	New on ART	7,358



	Already on ART at beginning of current pregnancy	7,241
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	7,858
	Male 15-19	524
	Male 20-24	591
	Male 50+	500
	Female 15-19	844
	Female 20-24	1,110
	Female 50+	656
	FSW	933
	MSM	1,145
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	613
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	353
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	591
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	353
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	534
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	353
PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	513	



	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	329
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	199,136
	Age/sex: 15-19 Male	8,315
	Age/sex: 20-24 Male	17,116
	Age/sex: 50+ Male	7,570
	Age/sex: 10-14 Female	12
	Age/sex: 15-19 Female	12,995
	Age/sex: 20-24 Female	25,782
	Age/sex: 50+ Female	1
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	18,396
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	23,555
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	9,336
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	21,845
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	6,510
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	19,806
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	3,916



	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	23,981
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	67,967
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,791
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	23,066
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are	48



	based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	218
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	42,844
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	98 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	19,003
	Total number of registered new and relapsed TB cases, during the reporting period.	19,478
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	458
	Aggregated Age/Sex: Male 15+	11,072



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	487
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,986
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	452
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	11,578
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	475
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6,973
HTS_SELF_DSD	HTS_SELF_N_DSD	42,338
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	1,170
	HTS_SELF_N_DSD_Age_Sex_HI	16,295



	VSelfTest 20-24, Male, Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	1,897
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	6,973
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	1,495
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	5,591
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	846
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	3,059
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	156
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	3,405
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	42
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	1,364
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	42,338
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	24,411
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Sex Partner	17,926
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Unassisted	92
	HTS_SELF_N_DSD_KeyPop_HIV	24,354



	SelfTest MSM, Unassisted	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,268,224
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	8,174
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	342
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4,998
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	207
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	19,374
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2,079
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	17,312
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1,864
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	15,846
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1,703
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	14,596
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1,564
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	10,772
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1,152
Service Delivery Point (Facility)	8,783	



	Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility)	936
	Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility)	5,649
	Inpatient: <1, Negative	
	Service Delivery Point (Facility)	232
	Inpatient: <1, Positive	
	Service Delivery Point (Facility)	31,802
	Inpatient: 1-9, Negative	
	Service Delivery Point (Facility)	1,328
	Inpatient: 1-9, Positive	
	Service Delivery Point (Community)	703
	Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community)	31
	Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community)	451
	Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community)	13
	Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community)	10,353
	Mobile Testing: 15-19, Female, Negative	
	Service Delivery Point (Community)	839
	Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community)	8,996
	Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community)	742
	Mobile Testing: 15-19, Male, Positive	



	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	8,840
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	708
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	7,680
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	618
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	5,604
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	456
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	4,701
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	382
	Service Delivery Point (Community) Mobile Testing: <1, Negative	494
	Service Delivery Point (Community) Mobile Testing: <1, Positive	12
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	2,612
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	117
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	42,172
	Service Delivery Point (Facility)	422



	Other PITC: 10-14, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	25,775
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	265
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	109,080
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	5,915
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	96,981
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	5,282
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	88,305
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4,832
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	81,470
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	4,472
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	60,988
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3,278
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	51,104
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	2,692



Service Delivery Point (Facility) Other PITC: <1, Negative	29,132
Service Delivery Point (Facility) Other PITC: <1, Positive	290
Service Delivery Point (Facility) Other PITC: 1-9, Negative	163,998
Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,656
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,941
Service Delivery Point (Community) Other: 10-14, Female, Positive	6
Service Delivery Point (Community) Other: 10-14, Male, Negative	1,754
Service Delivery Point (Community) Other: 10-14, Male, Positive	1
Service Delivery Point (Community) Other: 15-19, Female, Negative	6,358
Service Delivery Point (Community) Other: 15-19, Female, Positive	163
Service Delivery Point (Community) Other: 15-19, Male, Negative	5,640
Service Delivery Point (Community) Other: 15-19, Male, Positive	143
Service Delivery Point (Community) Other: 20-24, Female, Negative	5,275
Service Delivery Point (Community) Other: 20-24, Female, Positive	139
Service Delivery Point (Community) Other: 20-24, Male, Negative	4,724
Service Delivery Point (Community) Other: 20-24, Male, Positive	122
Service Delivery Point (Community)	3,528



	Other: 50+, Female, Negative	
	Service Delivery Point (Community)	90
	Other: 50+, Female, Positive	
	Service Delivery Point (Community)	2,749
	Other: 50+, Male, Negative	
	Service Delivery Point (Community)	68
	Other: 50+, Male, Positive	
	Service Delivery Point (Community)	2,109
	Other: <1, Negative	
	Service Delivery Point (Community)	4
	Other: <1, Positive	
	Service Delivery Point (Community)	11,566
	Other: 1-9, Negative	
	Service Delivery Point (Community)	53
	Other: 1-9, Positive	
	Service Delivery Point (Facility)	1,153
	Pediatric : <5 Negative	
	Service Delivery Point (Facility)	147
	Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB:	187
	10-14, Female, Negative	
	Service Delivery Point (Facility) TB:	6
	10-14, Female, Positive	
	Service Delivery Point (Facility) TB:	164
	10-14, Male, Negative	
	Service Delivery Point (Facility) TB:	7
	10-14, Male, Positive	
	Service Delivery Point (Facility) TB:	545
	15-19, Female, Negative	
	Service Delivery Point (Facility) TB:	12
	15-19, Female, Positive	
	Service Delivery Point (Facility) TB:	515
	15-19, Male, Negative	
	Service Delivery Point (Facility) TB:	9



	15-19, Male, Positive	
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	699
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	48
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	916
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
	Service Delivery Point (Facility) TB: 50+, Female, Negative	1,131
	Service Delivery Point (Facility) TB: 50+, Female, Positive	110
	Service Delivery Point (Facility) TB: 50+, Male, Negative	1,705
	Service Delivery Point (Facility) TB: 50+, Male, Positive	159
	Service Delivery Point (Facility) TB: <1, Negative	24
	Service Delivery Point (Facility) TB: 1-9, Negative	355
	Service Delivery Point (Facility) TB: 1-9, Positive	9
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2,047
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	509
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,243
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	313
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	12,757
	Service Delivery Point (Facility)	4,032



	Index: 15-19, Female, Positive	
	Service Delivery Point (Facility)	11,457
	Index: 15-19, Male, Negative	
	Service Delivery Point (Facility)	3,580
	Index: 15-19, Male, Positive	
	Service Delivery Point (Facility)	10,409
	Index: 20-24, Female, Negative	
	Service Delivery Point (Facility)	3,303
	Index: 20-24, Female, Positive	
	Service Delivery Point (Facility)	9,673
	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	3,043
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	7,094
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	2,241
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	5,806
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	1,836
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	1,418
	Index: <1, Negative	
	Service Delivery Point (Facility)	350
	Index: <1, Positive	
	Service Delivery Point (Facility)	7,950
	Index: 1-9, Negative	
	Service Delivery Point (Facility)	1,972
	Index: 1-9, Positive	
	By Key Population: FSW, Negative	28,767
	By Key Population: FSW, Positive	2,555
	By Key Population: MSM, Negative	9,449
	By Key Population: MSM, Positive	1,033
	By Key Population: TG, Negative	32



	By Key Population: TG, Positive	3
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	179
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	43
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	106
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	22
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2,666
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	672
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	2,365
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	600
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2,209
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	558
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,989
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	496
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1,476
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	370
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	1,156



	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	291
	Service Delivery Point (Community) Index Mod: <1, Negative	132
	Service Delivery Point (Community) Index Mod: <1, Positive	28
	Service Delivery Point (Community) Index Mod: 1-9, Negative	698
	Service Delivery Point (Community) Index Mod: 1-9, Positive	177
	Service Delivery Point (Facility) ANC: 10-14, Negative	1,966
	Service Delivery Point (Facility) ANC: 10-14, Positive	1
	Service Delivery Point (Facility) ANC: 15-19, Negative	91,958
	Service Delivery Point (Facility) ANC: 15-19, Positive	398
	Service Delivery Point (Facility) ANC: 20-24, Negative	157,485
	Service Delivery Point (Facility) ANC: 20-24, Positive	1,464
	Service Delivery Point (Facility) ANC: 50+, Negative	632
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	18
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	22
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	105



	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	4
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	9
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	183
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	11
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	57
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	3
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	132
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	11
	Service Delivery Point (Facility) VCT: <1, Negative	7
	Service Delivery Point (Facility) VCT: 1-9, Negative	7
	HTS_TST_N_DSD_EW_Age_Sex_ Result <1, Unknown Sex, Negative	790
	HTS_TST_N_DSD_EW_Age_Sex_ Result <1, Unknown Sex, Positive	3
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Negative	1,147
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Positive	8
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Negative	721



HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Positive	4
HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Negative	18,437
HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Positive	1,393
HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Negative	16,458
HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Positive	1,268
HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Negative	4,599
HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Positive	53
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Negative	15,123
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Positive	1,158
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Negative	13,884
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Positive	1,075
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Negative	1,069
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Positive	79
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Negative	6,232
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Positive	461
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Negative	1,076
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Positive	80



HTS_TST_N_DSD_EW_Age_Sex_	6,274
Result 30-34, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	462
Result 30-34, Male, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	1,069
Result 35-39, Female, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	78
Result 35-39, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	5,655
Result 35-39, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	424
Result 35-39, Male, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	1,063
Result 40-49, Female, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	77
Result 40-49, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	5,105
Result 40-49, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	386
Result 40-49, Male, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	10,219
Result 50+, Female, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	742
Result 50+, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	8,307
Result 50+, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	611
Result 50+, Male, Positive	
HTS_TST_N_DSD_Index_Age_Se	753
x_Result 25-29, Female, Negative	
HTS_TST_N_DSD_Index_Age_Se	234
x_Result 25-29, Female, Positive	
HTS_TST_N_DSD_Index_Age_Se	4,270
x_Result 25-29, Male, Negative	



HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	1,360
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	756
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	237
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	4,281
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	1,367
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	753
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	234
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	3,856
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	1,226
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	752
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	232
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	3,489
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	1,103
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,162
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	123
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	6,498
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	690



HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Negative	1,166
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Positive	123
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Negative	6,526
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Positive	691
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Negative	1,162
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	123
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	5,881
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	623
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	1,158
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	122
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	5,322
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	563
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	787
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	61
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	4,486
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	318



HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	826
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	66
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	4,736
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	329
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	787
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	61
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	4,219
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	287
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	749
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	57
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	3,636
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	255
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	27,302
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	1,898



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	156
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	35
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	870
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	223
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	157
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	35
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	874
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	224
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	156
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	35
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	800
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	207
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	156
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	34



	Positive	
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	711
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	179
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	6,639
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	377
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	37,466
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1,992
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	6,672
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	383
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	37,684
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	2,005
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	6,639
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	377
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	33,479
	HTS_TST_N_DSD_OtPITC_Age_	1,776



	Sex_Result 35-39, Male, Positive	
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative	6,606
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Positive	370
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Negative	30,767
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Positive	1,583
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female, Negative	376
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female, Positive	5
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Negative	2,033
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Positive	44
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Female, Negative	376
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Female, Positive	5
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Male, Negative	2,033
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Male, Positive	44
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 35-39, Female, Negative	376



HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	5
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	1,868
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	42
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	376
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	5
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	1,663
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	36
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	163,741
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	2,349
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	108,631
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	1,866
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	68,845
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	1,045



HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	21,748
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	210
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	10,687
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	688
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	9,580
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	605
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	8,743
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	530
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	8,062
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	503
HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	606
HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	28
HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	3,472
HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	205
HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	606
HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	28



HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	3,472
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	206
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	606
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	28
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	3,146
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	192
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	606
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	28
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	2,838
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	177
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	5,950
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	358
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	4,779
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	283
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Negative	726
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Positive	76
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Negative	1,322



HTS_TST_N_DSD_TBC_Age_Sex _Result 25-29, Male, Positive	35
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Negative	849
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Positive	128
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Negative	1,427
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Positive	70
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	627
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	131
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	1,343
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	151
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	881
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	202
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	1,767
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	212
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	73
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	11
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	476
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	24



	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	88
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	13
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	571
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	29
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	73
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	11
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	476
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	24
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	59
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	9
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	381
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	20
GEND_GBV_DSD	Number of people receiving post-GBV care	762
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	95
	By type of service: Sexual Violence (Post-Rape Care)	667
	By PEP service provision (related to sexual violence services provided)	548



	<10, Female, Physical and/or Emotional Violence	4
	<10, Female, Sexual Violence (Post-Rape Care)	96
	<10, Male, Physical and/or Emotional Violence	8
	<10, Male, Sexual Violence (Post-Rape Care)	8
	10-14, Female, Physical and/or Emotional Violence	3
	10-14, Female, Sexual Violence (Post-Rape Care)	179
	10-14, Male, Physical and/or Emotional Violence	5
	10-14, Male, Sexual Violence (Post-Rape Care)	17
	15-19, Female, Physical and/or Emotional Violence	18
	15-19, Female, Sexual Violence (Post-Rape Care)	186
	15-19, Male, Sexual Violence (Post-Rape Care)	2
	20-24, Female, Physical and/or Emotional Violence	16
	20-24, Female, Sexual Violence (Post-Rape Care)	76
	20-24, Male, Physical and/or Emotional Violence	1
	50+, Female, Sexual Violence (Post-Rape Care)	7
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	28
	GEND_GBV_N_DSD_Age_Sex_Vi	60



	olenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	3
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	14
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	7
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	3
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	1
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	17
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	1
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	259,802
	Age/Sex: 10-14 Male	25,862
	Age/Sex: 15-17 Male	25,861



	By: Age/sex: Male 18-24	8,768
	By: Age/sex: Male 25+	20,458
	Age/Sex: 10-14 Female	48,412
	Age/Sex: 15-17 Female	31,231
	By: Age/sex: 18-24 Female	15,397
	By: Age/sex: 25+ Female	30,687
	Sum of Age/Sex disaggregates	131,366
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	3,848
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,996
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,330
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	2,577
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,337
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	890
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	4,492



	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2,330
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1,552
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	3,106
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,612
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,073
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,106
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,612
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,073
	Age/Sex: <1	10,341
	Age/Sex: 1-9	42,785
	Program Completion: Active	233,822
	Program Completion: Graduation	25,980
	OVC_SERV_N_DSD_Age_Sex_Ser vice_v4 1-9, Unknown Sex,	620



	Economic Strengthening	
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Education Support	770
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Other Service Areas	620
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Parenting/Caregiver Programs	516
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	899
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	41,600
	Age/Sex: 10-14 Male	4,369
	Age/Sex: 15-17 Male	4,175
	By age/sex: 18-24 Male	1,440
	By age/sex: 25+ Male	3,541
	Age/Sex: 10-14 Female	6,944
	Age/Sex: 15-17 Female	4,543
	By age/sex: 18-24 Female	2,195
	By age/sex: 25+ Female	5,246
	Sum of Age/Sex disaggregates	20,031
	Age/Sex: <1	1,657
	Age/Sex: 1-9	7,490
	Program Completion: Active	37,439
Program Completion: Graduated	4,161	
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC	71 %



	implementing partner.	
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	184,490
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	259,802
OVC_HIVSTAT_TA	OVC_HIVSTAT_TA Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	70 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	29,178
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	41,600
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,260
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented	50



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,950
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	60
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,185
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	32 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	67,628
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting	208,538



	period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	8,157
	By Age/Sex (Denominator): <15, Male	7,088
	By Age/Sex (Denominator): 15+, Female	86,384
	By Age/Sex (Denominator): 15+, Male	106,917
	By Age/Sex (Numerator): <15, Female	2,583
	By Age/Sex (Numerator): <15, Male	2,228
	By Age/Sex (Numerator): 15+, Female	28,108
	By Age/Sex (Numerator): 15+, Male	34,715
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	208,538
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	67,628
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	420,891
	Denominator: By Aggregated Age/Sex: <15, Female	18,249



	Denominator: By Aggregated Age/Sex: <15, Male	16,087
	Denominator: By Aggregated Age/Sex:15+, Female	171,680
	Denominator: By Aggregated Age/Sex:15+, Male	214,870
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	978
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	180
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	760
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	38
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	395,612
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	603
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	24,507
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	810
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women	n/a



	that receive a virological HIV test within 12 months of birth (DSD)	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	14,207
	By infants who received a virologic test within 2 months of birth	11,358
	By infants who received their first virologic HIV test between 2 and 12 months of age	2,849
	Sum of Infant Age disaggregates	14,207
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	421,173
	Age/Sex: 15-19 Male	31,009
	Age/Sex: 15-19 Female	40,815
	Age/Sex: <1	2,381
	Age/Sex: <1-9	17,727
	Age/Sex: 10-14 Male	3,604
	Age/Sex: 10-14 Female	4,846
	Age/Sex: 20-24 Male	27,177
	Age/Sex: 50+ Male	33,265
	Age/Sex: 20-24 Female	35,183
	Age/Sex: 50+ Female	42,645
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	27,457
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	20,100
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	27,524
TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	20,246	
TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	23,596	



	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	20,100
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	23,528
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	19,954
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	128,907
	By Age/Sex: <1	1,260
	By Age/Sex: 1-9	7,143
	By Age/Sex: 10-14 Male	1,152
	By Age/Sex: 15-19 Male	17,575
	By Age/Sex: 20-24 Male	14,815
	By Age/Sex: 50+ Male	8,911
	By Age/Sex: 10-14 Female	1,837
	By Age/Sex: 15-19 Female	19,649
	By Age/Sex: 20-24 Female	16,145
	By Age/Sex: 50+ Female	10,927
	Pregnancy status	17,325
	Breastfeeding status	1,556
	FSW	335
	MSM	233
	People in prisons and other enclosed settings	17
	TG	1
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	1,194
TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	6,623	
TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	1,212	
TX_NEW_N_DSD_Age_Sex_HIVS	6,659	



	tatus 30-34, Male, Positive	
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	1,194
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	6,000
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	1,178
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	5,397
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	400,515
	Denominator: Indication: Routine	400,515
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	10,913
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	97,306
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	10,628
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	281,670
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	95 %
	Number of adults and children who	125,737



	are still alive and on treatment at 12 months after initiating ART	
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	132,629
	Numerator by Status: Pregnant	2,010
	Numerator by Status: Breastfeeding	8,753
	Denominator by Status: Pregnant	2,041
	Denominator by Status: Breastfeeding	9,718
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,706
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29,482
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,150
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90,398



	<p>Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>2,898</p>
	<p>Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>31,993</p>
	<p>Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>3,251</p>
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>94,484</p>



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9419	American Society for Microbiology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,573,624
11491	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,427,000
13602	Management Sciences for Health	NGO	U.S. Agency for International Development		
14073	Agence Ivoirienne de Marketing Social	NGO	U.S. Agency for International Development	GHP-State	562,320
14122	FHI 360	NGO	U.S. Agency for International Development		
16685	Abt Associates	Private Contractor	U.S. Agency for International Development		
16691	Johns Hopkins	University	U.S. Agency for		



	University Bloomberg School of Public Health		International Development		
16747	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16861	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development		
17014	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	764,000
17494	Health Alliance International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,662,876
17496	Population Services International	NGO	U.S. Department of Defense		
17515	Save The Children Federation Inc	NGO	U.S. Agency for International Development	GHP-State	8,344,999
17583	University of North Carolina at Chapel Hill,	University	U.S. Agency for International Development	GHP-State	844,481



	Carolina Population Center				
17602	UNICEF	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
17610	Aga Khan Foundation	NGO	U.S. Agency for International Development		
17763	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,941,119
17872	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development		
17903	Emory University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17914	ITECH	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,947,253
17942	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	1,820,290



18287	Heartland Alliance	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,943,209
18288	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,736,796
18289	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,064,641
18290	International Rescue Committee	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,696,090
18291	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,313,023
18292	Sante Espoir Vie -	NGO	U.S. Department	GHP-State	2,952,027



	Cote d'Ivoire		of Health and Human Services/Centers for Disease Control and Prevention		
18293	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,875,243
18294	Pasteur Institute of Ivory Coast	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	868,482
18295	Ministry of Health and Public Hygiene, Cote d'Ivoire	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,044,739
18296	Ministry of Family, Women, and Social Affairs, Cote d'Ivoire	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,230,479
18377	TBD	TBD	Redacted	Redacted	Redacted
18378	Global Health	Private Contractor	U.S. Agency for		



	Supply Chain Program		International Development		
18382	Chemonics International	Private Contractor	U.S. Agency for International Development		
18423	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development		
18431	UNAIDS II	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	571,000
18435	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18595	Sante Espoir Vie - Cote d'Ivoire	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,432,160
18596	ACONDA	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,723,710



18597	Fondation Ariel Glaser Pour la Lutte Contre le Sida Pediatrique en Cote D'Ivoire	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	8,524,005
18606	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-State	3,333,538
18607	MSH/Leadership Management & Sustainability (LMS)	Implementing Agency	U.S. Agency for International Development		
18610	TBD	TBD	Redacted	Redacted	Redacted
18639	JHPIEGO	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	150,000
70038	TBD	TBD	Redacted	Redacted	Redacted
70057	TBD	TBD	Redacted	Redacted	Redacted
70058	[Placeholder]	TBD	U.S. Agency for International Development		
70059	TBD	TBD	Redacted	Redacted	Redacted
70060	TBD	TBD	Redacted	Redacted	Redacted
70061	[Placeholder]	TBD	U.S. Agency for International Development		
70062	TBD	TBD	Redacted	Redacted	Redacted

Approved



70503	[Placeholder]	TBD	U.S. Department of State/Office of the Global AIDS Coordinator		
-------	---------------	-----	--	--	--



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 9419	Mechanism Name: CDC Lab Coalition
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,573,624	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,573,624	
Funding Source	Funding Amount
GHP-State	2,573,624

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9419		
Mechanism Name: CDC Lab Coalition		
Prime Partner Name: American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	2,096,760
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	276,864
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	200,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11491	Mechanism Name: CDC-RETRO-CI GHAI
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,427,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,427,000	
Funding Source	Funding Amount



GHP-State	2,427,000
-----------	-----------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	11491	
Mechanism Name:	CDC-RETRO-CI GHAI	
Prime Partner Name:	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	465,467
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,961,533
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13602	Mechanism Name: LMG (Leadership, Management and Governance Project)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13602	
Mechanism Name:	LMG (Leadership, Management and Governance Project)	
Prime Partner Name:	Management Sciences for Health	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14073	Mechanism Name: Sustainable Condoms Solutions Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Agence Ivoirienne de Marketing Social	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 562,320	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 562,320	
Funding Source	Funding Amount



GHP-State	562,320
-----------	---------

Cross-Cutting Budget Attribution(s)

Condom programming	254,914
--------------------	---------

Budget Code Information

Mechanism ID: 14073		
Mechanism Name: Sustainable Condoms Solutions Project		
Prime Partner Name: Agence Ivoirienne de Marketing Social		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	249,920



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	162,141
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	150,259
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14122	Mechanism Name: FANTA3 (Food and Nutrition Technical Assistance)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14122		
Mechanism Name: FANTA3 (Food and Nutrition Technical Assistance)		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16685	Mechanism Name: HFG (Health Finance and Governance)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16685 Mechanism Name: HFG (Health Finance and Governance) Prime Partner Name: Abt Associates		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16691	Mechanism Name: HC3
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16691		
Mechanism Name: HC3		
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16747	Mechanism Name: JHPIEGO CoAg 2013
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 16747 Mechanism Name: JHPIEGO CoAg 2013 Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16861	Mechanism Name: ASSIST
----------------------------	-------------------------------



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16861		
Mechanism Name: ASSIST		
Prime Partner Name: University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17014	Mechanism Name: FHI360_ Surveillance and Program Evaluation
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 764,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 764,000	
Funding Source	Funding Amount
GHP-State	764,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17014		
Mechanism Name: FHI360_ Surveillance and Program Evaluation		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	280,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	216,912
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	267,088
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17494	Mechanism Name: HAI coag2015
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Health Alliance International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,662,876	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,662,876	
Funding Source	Funding Amount
GHP-State	6,662,876

Cross-Cutting Budget Attribution(s)

Gender: GBV	285,442
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	32,625

Budget Code Information

Mechanism ID: 17494



Mechanism Name: HAI coag2015		
Prime Partner Name: Health Alliance International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	608,881
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	185,052
Strategic Area	Budget Code	Planned Amount
Care	PDCS	342,077
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	140,583
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	779,302
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,101,808
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	505,173

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,856
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	94,977
PMTCT_ART_DSD	New on ART	797
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,059



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	94,977
PMTCT_STAT_DSD	Number of new ANC and L&D clients	100,416
PMTCT_STAT_DSD	By Age (Denominator): 10-14	312
PMTCT_STAT_DSD	By Age (Denominator): <15-19	14,644
PMTCT_STAT_DSD	By Age (Denominator): 20-24	25,170
PMTCT_STAT_DSD	By Age (Denominator): 50+	57
PMTCT_STAT_DSD	By Number of known positives: 15-19	17
PMTCT_STAT_DSD	By Number of known positives: 20-24	117
PMTCT_STAT_DSD	By Number of new positives: 15-19	48
PMTCT_STAT_DSD	By Number of new positives: 20-24	165
PMTCT_STAT_DSD	By Number of new negative: 10-14	324
PMTCT_STAT_DSD	By Number of new negative: 15-19	13,873
PMTCT_STAT_DSD	By Number of new negative: 20-24	23,652
PMTCT_STAT_DSD	By Number of new negative: 50+	50
PMTCT_STAT_DSD	By Age (Numerator): 10-14	327
PMTCT_STAT_DSD	By Age (Numerator): 15-19	13,895
PMTCT_STAT_DSD	By Age (Numerator): 20-24	23,808
PMTCT_STAT_DSD	By Age (Numerator): 50+	57
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	26,641
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	18,103
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	11,785
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	3,704
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	337
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	24,271
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	249
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	343
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	16,585



	30-34, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	200
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	228
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	10,907
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	108
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	59
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	3,417
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	27
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	25,154
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	17,058
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	11,191
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	3,487
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	295,978
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,146
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	698
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,919
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	225



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,741
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	207
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,500
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	175
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,481
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	176
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,080
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	126
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	978
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	780
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	4,479
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	190
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,913
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3,602
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	16,125



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	687
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	14,799
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	631
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	12,582
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	534
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	12,677
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	544
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	9,027
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	383
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	8,247
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	348
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	4,026
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	23,097
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	236
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	288
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	174
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	45



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,720
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	467
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,592
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	430
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,345
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	368
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,366
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	368
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	959
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	263
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	868
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	238
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	198
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,119
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	278
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	324
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	13,846
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	23,548



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	1,987
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	150
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	1,825
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	137
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	655
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	1,569
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	1,560
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	123
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	693



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	693
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	597
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	1,108
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	987
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	65



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	609
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	609
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	530
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	496
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	134
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	118



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	673
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	673
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	580
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	556
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	3,832
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	267



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	989
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	5,709
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	227
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	989
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	5,709
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	227
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	989
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,921
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	195
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	989
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,717
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	184
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	24,427

HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	243
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	16,423
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	196
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	10,819
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3,393
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	1,110
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	1,025
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	868
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	872
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	3



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	380
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	380
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	331
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	312
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	619
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	547



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	151
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	22

TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,073
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,136
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,184
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	793
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	44
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,261
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	46
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	785
GEND_GBV_DSD	Number of people receiving post-GBV care	79
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	72
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	58



GEND_GBVDSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBVDSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	2
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	24
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	1
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	439
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	199
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with	222



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,803
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,440
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	363
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,803
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	55,034
TX_CURR_DSD	Age/Sex: 15-19 Male	4,075
TX_CURR_DSD	Age/Sex: 15-19 Female	5,284
TX_CURR_DSD	Sum of age/sex disaggregates	9,359
TX_CURR_DSD	Age/Sex: <1	346
TX_CURR_DSD	Age/Sex: <1-9	2,550
TX_CURR_DSD	Age/Sex: 10-14 Male	513
TX_CURR_DSD	Age/Sex: 10-14 Female	692
TX_CURR_DSD	Age/Sex: 20-24 Male	3,568
TX_CURR_DSD	Age/Sex: 50+ Male	4,396
TX_CURR_DSD	Age/Sex: 20-24 Female	4,585
TX_CURR_DSD	Age/Sex: 50+ Female	5,596
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,566
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,547
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,566
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,547
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,055
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male,	2,547



	Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,054
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,547
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,316
TX_NEW_DSD	By Age/Sex: <1	163
TX_NEW_DSD	By Age/Sex: 1-9	933
TX_NEW_DSD	By Age/Sex: 10-14 Male	152
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,948
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,663
TX_NEW_DSD	By Age/Sex: 50+ Male	1,061
TX_NEW_DSD	By Age/Sex: 10-14 Female	237
TX_NEW_DSD	By Age/Sex: 15-19 Female	2,123
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,672
TX_NEW_DSD	By Age/Sex: 50+ Female	1,183
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,039
TX_NEW_DSD	Pregnancy status	1,968
TX_NEW_DSD	Breastfeeding status	187
TX_NEW_DSD	FSW	44
TX_NEW_DSD	MSM	12
TX_NEW_DSD	TG	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	116
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	736
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	116
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	736
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	116



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	640
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	116
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	606
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	53,155
TX_PVLS_DSD	Denominator: Indication: Routine	53,155
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,525
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	12,641
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,412
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	37,577
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,244
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	18,142
TX_RET_DSD	Numerator by Status: Pregnant	277
TX_RET_DSD	Numerator by Status: Breastfeeding	1,114
TX_RET_DSD	Denominator by Status: Pregnant	294
TX_RET_DSD	Denominator by Status: Breastfeeding	1,250
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	570
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,975



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	661
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,038
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	601
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,300
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	678
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,563
HTS_SELF_DSD	HTS_SELF_N_DSD	546
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	122
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	170
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	133
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	93



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	546
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	546
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,010
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	5,802
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	209
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	177
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,427
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,991
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	108
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	92
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,260
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,551
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,802
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,010
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	55,800
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,739
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,419



TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	21,942
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	28,700
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	118
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	21
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	94
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	3
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	52,546
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	77
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	3,175
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	87

Implementing Mechanism Details

Mechanism ID: 17496	Mechanism Name: PSI Cote d'Ivoire
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17496		
Mechanism Name: PSI Cote d'Ivoire		
Prime Partner Name: Population Services International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	9
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10
PMTCT_ART_DSD	New on ART	1
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	8
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10
PMTCT_STAT_DSD	Number of new ANC and L&D clients	571
PMTCT_STAT_DSD	By Age (Denominator): 10-14	2
PMTCT_STAT_DSD	By Age (Denominator): <15-19	89
PMTCT_STAT_DSD	By Age (Denominator): 20-24	154
PMTCT_STAT_DSD	By Age (Denominator): 50+	2
PMTCT_STAT_DSD	By Number of known positives: 20-24	1
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	159
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	98
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	52
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	3
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	3
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	1



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,378
PP_PREV_DSD	Age/sex: 15-19 Male	4
PP_PREV_DSD	Age/sex: 20-24 Male	127
PP_PREV_DSD	Age/sex: 50+ Male	196
PP_PREV_DSD	Age/sex: 20-24 Female	7
PP_PREV_DSD	Sum of Age/Sex disaggregates	334
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	7
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	754
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	7
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	754
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	7
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	754
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	7
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	754
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	500
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,181
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	1



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	69
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	120



	20-24, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	86
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	7



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	288
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female,	5



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female,	46



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male,	21



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	3



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29,	35



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	13



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	375
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	272
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	9



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	327
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	272
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	218
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29,	18



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	143
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	5
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	9
PMTCT_EID_DSD	By infants who received a virologic test within 2 months	7



	of birth	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2
PMTCT_EID_DSD	Sum of Infant Age disaggregates	9
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,274
TX_CURR_DSD	Age/Sex: 15-19 Male	10
TX_CURR_DSD	Age/Sex: 15-19 Female	102
TX_CURR_DSD	Sum of age/sex disaggregates	112
TX_CURR_DSD	Age/Sex: <1	3
TX_CURR_DSD	Age/Sex: <1-9	3
TX_CURR_DSD	Age/Sex: 10-14 Male	40
TX_CURR_DSD	Age/Sex: 10-14 Female	40
TX_CURR_DSD	Age/Sex: 20-24 Male	34
TX_CURR_DSD	Age/Sex: 50+ Male	273
TX_CURR_DSD	Age/Sex: 20-24 Female	254
TX_CURR_DSD	Age/Sex: 50+ Female	20
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	276
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	598
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	331
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	717
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	276
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	598
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	221
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	478



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	316
TX_NEW_DSD	By Age/Sex: 10-14 Male	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	1
TX_NEW_DSD	By Age/Sex: 20-24 Male	3
TX_NEW_DSD	By Age/Sex: 50+ Male	20
TX_NEW_DSD	By Age/Sex: 10-14 Female	3
TX_NEW_DSD	By Age/Sex: 15-19 Female	8
TX_NEW_DSD	By Age/Sex: 20-24 Female	19
TX_NEW_DSD	By Age/Sex: 50+ Female	1
TX_NEW_DSD	Sum of Age/Sex disaggregates	58
TX_NEW_DSD	Pregnancy status	1
TX_NEW_DSD	Breastfeeding status	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	20
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	44
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	53
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	20
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	44
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	16
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	36
HTS_SELF_DSD	HTS_SELF_N_DSD	462
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29,	9



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	393
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	46
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	462
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	439
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	23
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	23

Implementing Mechanism Details

Mechanism ID: 17515	Mechanism Name: REVE Reducing Vulnerability in Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Save The Children Federation Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,344,999	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 520,798	
Total All Funding Sources and Applied Pipeline Amount: 8,865,797	
Funding Source	Funding Amount
GHP-State	8,344,999

Cross-Cutting Budget Attribution(s)

Gender: GBV	110,000
-------------	---------



Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Water	200,000
Condom programming	418,043
Economic Strengthening	500,000
Adolescent Girls and Young Women (AGYW)	3,140,000
Education	550,000
Food and Nutrition: Policy, Tools, and Service Delivery	300,000

Budget Code Information

Mechanism ID: 17515		
Mechanism Name: REVE Reducing Vulnerability in Children		
Prime Partner Name: Save The Children Federation Inc		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	250,570
Strategic Area	Budget Code	Planned Amount
Care	HKID	4,446,565
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,895,538
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	642,326
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	110,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,672
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	88
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	557
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	480
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	446
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	389



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	319
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	266
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	341
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	394
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	244
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	989
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	866
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	811
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	721



HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	551
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	439
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	271
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	1,518
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	167
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	144
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	135
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	16



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	120
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	93
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	92
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	32

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	5



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	319
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	319
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	289
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	261
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	5
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	82,666
OVC_SERV_DSD	Age/Sex: 10-14 Male	8,175
OVC_SERV_DSD	Age/Sex: 15-17 Male	8,175
OVC_SERV_DSD	By: Age/sex: Male 18-24	2,748
OVC_SERV_DSD	By: Age/sex: Male 25+	6,409
OVC_SERV_DSD	Age/Sex: 10-14 Female	15,685
OVC_SERV_DSD	Age/Sex: 15-17 Female	10,072
OVC_SERV_DSD	By: Age/sex: 18-24 Female	4,917



OVC_SERV_DSD	By: Age/sex: 25+ Female	9,616
OVC_SERV_DSD	Sum of Age/Sex disaggregates	42,107
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,915
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	993
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	662
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,915
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	993
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	662
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	2,462
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,277
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,462
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,277
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	851
OVC_SERV_DSD	Age/Sex: <1	3,268
OVC_SERV_DSD	Age/Sex: 1-9	13,601
OVC_SERV_DSD	Program Completion: Active	74,400
OVC_SERV_DSD	Program Completion: Graduation	8,266
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Economic Strengthening	492
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Education Support	383



OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Other Service Areas	492
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	383
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	58,974
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	82,666

Implementing Mechanism Details

Mechanism ID: 17583	Mechanism Name: Measure Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 844,481	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 844,481	
Funding Source	Funding Amount
GHP-State	844,481

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	400,000
---	---------

Budget Code Information



Mechanism ID:	17583	
Mechanism Name:	Measure Evaluation Phase IV	
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	34,053
Strategic Area	Budget Code	Planned Amount
Care	HKID	292,815
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	34,053
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	51,080
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	306,481
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	125,999

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17602	Mechanism Name: New CDC Award to UNICEF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 150,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17602		
Mechanism Name: New CDC Award to UNICEF		
Prime Partner Name: UNICEF		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	150,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17610	Mechanism Name: Telemedicine in Côte d'Ivoire
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Aga Khan Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17610



Mechanism Name: Telemedicine in Côte d'Ivoire		
Prime Partner Name: Aga Khan Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17763	Mechanism Name: LINKAGES
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 1,941,119	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,941,119	
Funding Source	Funding Amount
GHP-State	1,941,119

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	127,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	144,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	90,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building



Budget Code Information

Mechanism ID: 17763 Mechanism Name: LINKAGES Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	456,487
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	27,460
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	771,689
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	148,003
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	537,480
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in	1,034



	the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Male 15-19	32
PrEP_NEW_DSD	Male 20-24	92
PrEP_NEW_DSD	Male 50+	21
PrEP_NEW_DSD	Female 15-19	103
PrEP_NEW_DSD	Female 20-24	289
PrEP_NEW_DSD	Female 50+	11
PrEP_NEW_DSD	FSW	476
PrEP_NEW_DSD	MSM	558
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	103
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	92
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	92
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	21
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	30,867
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	612
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,139
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV	25



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	31
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	19,060
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,647
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,087
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	233
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,835
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	206
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,712
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	193
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,528
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	171
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	1,170
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	128



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	925
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	102
HTC_TST_DSD	By Key Population: FSW, Negative	11,868
HTC_TST_DSD	By Key Population: FSW, Positive	979
HTC_TST_DSD	By Key Population: MSM, Negative	3,967
HTC_TST_DSD	By Key Population: MSM, Positive	444
HTC_TST_DSD	By Key Population: TG, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	643
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	217
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	569
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	194
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	531
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	178
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	474
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	159
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	359
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	123
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	280
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29,	124



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	676
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	124
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	676
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	124
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	613
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	124
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	553
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	10



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	186
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	55
HTS_SELF_DSD	HTS_SELF_N_DSD	10,452
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	3,973
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2,613



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2,093
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,044
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	523
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	206
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	10,452
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	5,226
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	5,226
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	10,455

Implementing Mechanism Details

Mechanism ID: 17872	Mechanism Name: Global Health Supply Chain Quality Assurance
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17872 Mechanism Name: Global Health Supply Chain Quality Assurance Prime Partner Name: Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17903	Mechanism Name: African Health Profession Regulatory Collaborative for Nurses and
----------------------------	--



Midwives (ARC)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Emory University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17903	
Mechanism Name:	African Health Profession Regulatory Collaborative for Nurses and Midwives (ARC)	
Prime Partner Name:	Emory University	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17914	Mechanism Name: LABQUASY - Itech/University of washington CoAg
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: ITECH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,947,253	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,947,253	
Funding Source	Funding Amount
GHP-State	2,947,253

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17914 Mechanism Name: LABQUASY - Itech/University of washington CoAg Prime Partner Name: ITECH		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	600,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	200,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,147,253
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17942	Mechanism Name: PRIVATE SECTOR HEALTH PROJECT
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,820,290	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,820,290	
Funding Source	Funding Amount
GHP-State	1,820,290

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17942		
Mechanism Name: PRIVATE SECTOR HEALTH PROJECT		
Prime Partner Name: Abt Associates		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	392,201
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	81,950
Strategic Area	Budget Code	Planned Amount



Care	PDCS	149,953
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	124,875
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	450,075
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	79,668



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	449,272
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	92,296

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	290
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,068
PMTCT_ART_DSD	New on ART	187
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	103
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,068
PMTCT_STAT_DSD	Number of new ANC and L&D clients	10,977
PMTCT_STAT_DSD	By Age (Denominator): 10-14	27
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,562
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,750
PMTCT_STAT_DSD	By Age (Denominator): 50+	13
PMTCT_STAT_DSD	By Number of known positives: 20-24	11
PMTCT_STAT_DSD	By Number of new positives: 15-19	7
PMTCT_STAT_DSD	By Number of new positives: 20-24	38



PMTCT_STAT_DSD	By Number of new negative: 10-14	26
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,435
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,502
PMTCT_STAT_DSD	By Number of new negative: 50+	12
PMTCT_STAT_DSD	By Age (Numerator): 10-14	26
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,456
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,464
PMTCT_STAT_DSD	By Age (Numerator): 50+	12
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,903
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,023
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,256
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	443
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	29
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	2,507
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	62
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	36
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,789
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	49
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	25
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,115
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	26
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	388



	40-49, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	5
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	2,683
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,863
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,160
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	404
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	71,119
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	203
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	116
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	957
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	870
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	106
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	802
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	744
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	92



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	520
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	381
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	150
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	815
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,043
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	587
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	4,808
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	282
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	4,179
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	251
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4,069
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	271
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,587



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	217
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,670
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	168
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,074
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	721
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4,140
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	704
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	243
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	637
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	220



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	587
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	195
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	527
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	186
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	391
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	128
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	282
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	212
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,435
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,502
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19,	1,030



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	934
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	872
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	793
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	322
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	322
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39,	57



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	261
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	562
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	419
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	13



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	203
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	298
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34,	298



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	282
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	240
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	499
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	289
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,541
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	96
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	289
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	15



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,541
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	96
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	289
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,426
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	289
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,257
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,608
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,789
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,115
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49,	388



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	605
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	550
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	515
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	469
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	12



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	334
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	247
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	16
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	282
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	229
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	53
PMTCT_EID_DSD	Sum of Infant Age disaggregates	282
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	14,609



TX_CURR_DSD	Age/Sex: 15-19 Male	1,144
TX_CURR_DSD	Age/Sex: 15-19 Female	1,455
TX_CURR_DSD	Sum of age/sex disaggregates	2,599
TX_CURR_DSD	Age/Sex: <1	59
TX_CURR_DSD	Age/Sex: <1-9	453
TX_CURR_DSD	Age/Sex: 10-14 Male	93
TX_CURR_DSD	Age/Sex: 10-14 Female	124
TX_CURR_DSD	Age/Sex: 20-24 Male	974
TX_CURR_DSD	Age/Sex: 50+ Male	1,175
TX_CURR_DSD	Age/Sex: 20-24 Female	1,219
TX_CURR_DSD	Age/Sex: 50+ Female	1,544
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	965
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	694
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	965
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	694
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	831
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	694
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	831
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	694
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,983
TX_NEW_DSD	By Age/Sex: <1	33
TX_NEW_DSD	By Age/Sex: 1-9	174
TX_NEW_DSD	By Age/Sex: 10-14 Male	25
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,063



TX_NEW_DSD	By Age/Sex: 20-24 Male	889
TX_NEW_DSD	By Age/Sex: 50+ Male	449
TX_NEW_DSD	By Age/Sex: 10-14 Female	42
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,143
TX_NEW_DSD	By Age/Sex: 20-24 Female	969
TX_NEW_DSD	By Age/Sex: 50+ Female	622
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,202
TX_NEW_DSD	Pregnancy status	966
TX_NEW_DSD	Breastfeeding status	84
TX_NEW_DSD	FSW	38
TX_NEW_DSD	MSM	29
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	62
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	352
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	62
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	352
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	62
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	336
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	62
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	279
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	13,480
TX_PVLS_DSD	Denominator: Indication: Routine	13,480
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	370



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,239
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	371
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,500
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,396
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,583
TX_RET_DSD	Numerator by Status: Pregnant	61
TX_RET_DSD	Numerator by Status: Breastfeeding	251
TX_RET_DSD	Denominator by Status: Pregnant	59
TX_RET_DSD	Denominator by Status: Breastfeeding	283
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	812
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,554
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	873



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,675

Implementing Mechanism Details

Mechanism ID: 18287	Mechanism Name: Key population Consortium - PROTECT
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Heartland Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,943,209	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,943,209	
Funding Source	Funding Amount
GHP-State	1,943,209

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	1,204,793
----------------------	-----------



Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	738,416
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID: 18287		
Mechanism Name: Key population Consortium - PROTECT		
Prime Partner Name: Heartland Alliance		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	696,582
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	597,622
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	350,814



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	298,191
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,052
PrEP_NEW_DSD	Male 15-19	31
PrEP_NEW_DSD	Male 20-24	95
PrEP_NEW_DSD	Male 50+	18
PrEP_NEW_DSD	Female 15-19	106
PrEP_NEW_DSD	Female 20-24	301
PrEP_NEW_DSD	Female 50+	10
PrEP_NEW_DSD	FSW	457
PrEP_NEW_DSD	MSM	587
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	106
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	31



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	95
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	31
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	95
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	31
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	18
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	35,100
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,179
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,927
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	23
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	187
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	21,784



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,361
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	3,254
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	345
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	2,927
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	313
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,719
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	286
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,476
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	263
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	1,794
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	190
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,381
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	148
HTC_TST_DSD	By Key Population: FSW, Negative	16,899
HTC_TST_DSD	By Key Population: FSW, Positive	1,576
HTC_TST_DSD	By Key Population: MSM, Negative	5,482
HTC_TST_DSD	By Key Population: MSM, Positive	589
HTC_TST_DSD	By Key Population: TG, Negative	21
HTC_TST_DSD	By Key Population: TG, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19,	776



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	260
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	695
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	232
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	643
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	215
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	587
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	197
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	430
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	144
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	336
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	112
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,037
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	19

	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,037
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	961
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	845
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	249
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	249



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	230
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	205
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	70
HTS_SELF_DSD	HTS_SELF_N_DSD	13,898
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	5,281
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3,476
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2,781
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,390
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	693
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	277
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	13,898
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted -	6,949



	Self	
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	6,949
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	13,899

Implementing Mechanism Details

Mechanism ID: 18288	Mechanism Name: EGPAF Djasso
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,736,796	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,736,796	
Funding Source	Funding Amount
GHP-State	6,736,796

Cross-Cutting Budget Attribution(s)

Gender: GBV	381,708
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	32,625
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	32,625

Budget Code Information

Mechanism ID: 18288		
Mechanism Name: EGPAF Djasso		
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	91,009
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	357,876



Strategic Area	Budget Code	Planned Amount
Care	PDCS	372,307
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	778,043
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	357,236
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,358,814
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	421,511

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,642
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,672
PMTCT_ART_DSD	New on ART	1,290
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,352
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,672
PMTCT_STAT_DSD	Number of new ANC and L&D clients	101,528
PMTCT_STAT_DSD	By Age (Denominator): 10-14	305
PMTCT_STAT_DSD	By Age (Denominator): <15-19	15,228
PMTCT_STAT_DSD	By Age (Denominator): 20-24	26,199
PMTCT_STAT_DSD	By Age (Denominator): 50+	154
PMTCT_STAT_DSD	By Number of known positives: 15-19	25
PMTCT_STAT_DSD	By Number of known positives: 20-24	159



PMTCT_STAT_DSD	By Number of known positives: 50+	4
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	68
PMTCT_STAT_DSD	By Number of new positives: 20-24	264
PMTCT_STAT_DSD	By Number of new negative: 10-14	303
PMTCT_STAT_DSD	By Number of new negative: 15-19	14,328
PMTCT_STAT_DSD	By Number of new negative: 20-24	24,418
PMTCT_STAT_DSD	By Number of new negative: 50+	141
PMTCT_STAT_DSD	By Age (Numerator): 10-14	305
PMTCT_STAT_DSD	By Age (Numerator): 15-19	14,424
PMTCT_STAT_DSD	By Age (Numerator): 20-24	24,839
PMTCT_STAT_DSD	By Age (Numerator): 50+	147
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	28,126
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	17,704
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	10,650
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	3,162
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	428
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	25,034
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	429
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	449
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	16,036
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	335
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	277
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	9,809
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	169



	35-39, Female, Newly Identified Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	72
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,899
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	24
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	25,889
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	16,799
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	10,259
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	3,010
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	328,663
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,202
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	806
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,015
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	300
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,626
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	262
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,370
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	234



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,161
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	211
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,719
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	173
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,504
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	744
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	4,454
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	186
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	6,201
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	4,161
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	18,977
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	858
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	16,274
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	741
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	14,634



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	668
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	13,230
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	610
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	10,970
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	494
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	9,912
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	434
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	3,824
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	22,968
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	232
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	204
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	311
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	299
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,854
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	585
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,609



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	506
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,442
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	457
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,321
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	415
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,063
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	338
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	949
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	300
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	185
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,117
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	279
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	302
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	14,295
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	24,398
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	263
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	141
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	2,663
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	199
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	2,281
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	173
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	647
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	2,070
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	160
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	1,868
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	151
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	923



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	151
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	923
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	151
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	786
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	151
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	763
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	1,527
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	1,341
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	100



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	649
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	204
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	649
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	204
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	555
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	176
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	538
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	170
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	178

HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,040
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,040
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	899
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	862
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	3,934
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	273



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,131
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	6,705
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	298
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,131
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	6,705
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	298
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,131
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	5,661
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	245
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,131
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	5,573
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	237
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	25,033



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	428
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	16,019
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	335
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	9,797
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	169
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,895
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	1,542
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	1,328
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,192
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,081
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	3



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	526
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	526
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	452
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	440
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	879
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	779



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	131
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	261
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	245
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	27



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,372
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,396
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	93
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,996
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	96
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,187
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	93
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,020
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	96
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,187
GEND_GBV_DSD	Number of people receiving post-GBV care	37
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	21



GEND_GBVDSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	2
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	1
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	628
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	277
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	333
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within	2,572

	12 months of birth during the reporting period	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,057
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	515
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,572
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	67,645
TX_CURR_DSD	Age/Sex: 15-19 Male	5,059
TX_CURR_DSD	Age/Sex: 15-19 Female	6,443
TX_CURR_DSD	Sum of age/sex disaggregates	11,502
TX_CURR_DSD	Age/Sex: <1	364
TX_CURR_DSD	Age/Sex: <1-9	2,713
TX_CURR_DSD	Age/Sex: 10-14 Male	545
TX_CURR_DSD	Age/Sex: 10-14 Female	729
TX_CURR_DSD	Age/Sex: 20-24 Male	4,433
TX_CURR_DSD	Age/Sex: 50+ Male	5,578
TX_CURR_DSD	Age/Sex: 20-24 Female	5,696
TX_CURR_DSD	Age/Sex: 50+ Female	6,963
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4,428
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,167
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,428
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,167
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,799
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,167
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,799



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,167
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	18,994
TX_NEW_DSD	By Age/Sex: <1	173
TX_NEW_DSD	By Age/Sex: 1-9	1,043
TX_NEW_DSD	By Age/Sex: 10-14 Male	188
TX_NEW_DSD	By Age/Sex: 15-19 Male	2,511
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,053
TX_NEW_DSD	By Age/Sex: 50+ Male	1,484
TX_NEW_DSD	By Age/Sex: 10-14 Female	280
TX_NEW_DSD	By Age/Sex: 15-19 Female	2,912
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,273
TX_NEW_DSD	By Age/Sex: 50+ Female	1,673
TX_NEW_DSD	Sum of Age/Sex disaggregates	13,374
TX_NEW_DSD	Pregnancy status	2,488
TX_NEW_DSD	Breastfeeding status	266
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	165
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,010
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	165
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,010
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	165
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	875
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	165
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	849



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	64,839
TX_PVLS_DSD	Denominator: Indication: Routine	64,839
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,580
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,185
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,547
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	46,527
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	28,445
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	29,930
TX_RET_DSD	Numerator by Status: Pregnant	414
TX_RET_DSD	Numerator by Status: Breastfeeding	2,120
TX_RET_DSD	Denominator by Status: Pregnant	427
TX_RET_DSD	Denominator by Status: Breastfeeding	2,310
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	406
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,729
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	468
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20,842



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	431
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,298
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	481
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,720
HTS_SELF_DSD	HTS_SELF_N_DSD	1,111
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	221
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	378
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	297
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	163
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,111
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted -	1,111

	Sex Partner	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12,792
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	33,471
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,452
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,294
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	13,687
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	17,044
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	546
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	484
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,243
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	6,520
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	33,471
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	12,792
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	70,089
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,355
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,002
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	27,970
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	35,762
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	163
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	12



	Specimen Sent]: Other (No Xpert)	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	148
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	3
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	65,711
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	85
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	4,278
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	108

Implementing Mechanism Details

Mechanism ID: 18289	Mechanism Name: Columbia University - ICAP - Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,064,641	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,064,641	
Funding Source	Funding Amount
GHP-State	6,064,641

Cross-Cutting Budget Attribution(s)

Gender: GBV	382,177
Focus Area:	GBV Prevention



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	32,625
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Water	32,625

Budget Code Information

Mechanism ID: 18289		
Mechanism Name: Columbia University - ICAP - Follow-on		
Prime Partner Name: Columbia University		
Strategic Area	Budget Code	Planned Amount



Care	HBHC	159,694
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	334,674
Strategic Area	Budget Code	Planned Amount
Care	PDCS	277,246
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	420,354



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	453,752
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,075,187
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	343,734

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,010
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	85,566
PMTCT_ART_DSD	New on ART	1,015
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	995
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	85,566



PMTCT_STAT_DSD	Number of new ANC and L&D clients	90,708
PMTCT_STAT_DSD	By Age (Denominator): 10-14	252
PMTCT_STAT_DSD	By Age (Denominator): <15-19	13,200
PMTCT_STAT_DSD	By Age (Denominator): 20-24	22,896
PMTCT_STAT_DSD	By Age (Denominator): 50+	121
PMTCT_STAT_DSD	By Number of known positives: 15-19	14
PMTCT_STAT_DSD	By Number of known positives: 20-24	112
PMTCT_STAT_DSD	By Number of known positives: 50+	3
PMTCT_STAT_DSD	By Number of new positives: 15-19	53
PMTCT_STAT_DSD	By Number of new positives: 20-24	194
PMTCT_STAT_DSD	By Number of new negative: 10-14	251
PMTCT_STAT_DSD	By Number of new negative: 15-19	12,490
PMTCT_STAT_DSD	By Number of new negative: 20-24	21,466
PMTCT_STAT_DSD	By Number of new negative: 50+	114
PMTCT_STAT_DSD	By Age (Numerator): 10-14	252
PMTCT_STAT_DSD	By Age (Numerator): 15-19	12,439
PMTCT_STAT_DSD	By Age (Numerator): 20-24	21,524
PMTCT_STAT_DSD	By Age (Numerator): 50+	119
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	24,755
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	16,413
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	9,944
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	3,127
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	305
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	22,181
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	330
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	339
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	14,955



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	264
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	215
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	9,178
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	144
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	58
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,869
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	27
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	23,392
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	15,424
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	9,468
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,949
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,116
PrEP_NEW_DSD	Male 15-19	169
PrEP_NEW_DSD	Male 20-24	148
PrEP_NEW_DSD	Male 50+	169
PrEP_NEW_DSD	Female 15-19	233
PrEP_NEW_DSD	Female 20-24	190
PrEP_NEW_DSD	Female 50+	233
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	148
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	106
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	148
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	106
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	127
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	106



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	127
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	106
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	269,213
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	815
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	497
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,050
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	313
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,749
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	287
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,546
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	263
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,331
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	242
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,681
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	165
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male,	1,294



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	130
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	565
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,172
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	131
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	4,211
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	2,577
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	12,833
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	924
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	11,640
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	839
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	10,546
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	740
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	9,758
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	716
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	7,099
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+,	494



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,587
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	378
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	2,978
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	16,421
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	189



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	235
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	351
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	205
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,845
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	607
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,675
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	518
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,551
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	506
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,424
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	464



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,013
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	328
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	771
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	248
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	792
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	197
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	251
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	12,490
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	21,466
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	194
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	2,786
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	212
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	2,533
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	201



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	458
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	2,355
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	176
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	2,158
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	884
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	884
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	825



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	718
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	1,529
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	1,160
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	585
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	190
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	585
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	190



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	545
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	179
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	474
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	155
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	970
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	970
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	178



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	899
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	791
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	2,774
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	193
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	754
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,139
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	287
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	754
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,139
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	287



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	754
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,793
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	267
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	754
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,389
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	221
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	22,907
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	330
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	14,955
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	264
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	9,178
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,869
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	1,638



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	1,482
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	97
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,383
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	86
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,260
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	509
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	509
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	4



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	480
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	415
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	897
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	674
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	151
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	274
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	177
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	294



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	132
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	278
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	365
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	46
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,879
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,897
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	89
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,297
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	99
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,394



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	89
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,323
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	94
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,391
GEND_GBV_DSD	Number of people receiving post-GBV care	85
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	17
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	55
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	3
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	3
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	3



	25-29, Female, Physical and/or Emotional Violence	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	749
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	345
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	381
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within	1,969

	12 months of birth during the reporting period	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,574
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	395
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,969
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	61,238
TX_CURR_DSD	Age/Sex: 15-19 Male	4,573
TX_CURR_DSD	Age/Sex: 15-19 Female	6,054
TX_CURR_DSD	Sum of age/sex disaggregates	10,627
TX_CURR_DSD	Age/Sex: <1	342
TX_CURR_DSD	Age/Sex: <1-9	2,547
TX_CURR_DSD	Age/Sex: 10-14 Male	508
TX_CURR_DSD	Age/Sex: 10-14 Female	694
TX_CURR_DSD	Age/Sex: 20-24 Male	4,001
TX_CURR_DSD	Age/Sex: 50+ Male	4,801
TX_CURR_DSD	Age/Sex: 20-24 Female	5,141
TX_CURR_DSD	Age/Sex: 50+ Female	6,285
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4,002
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,857
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,002
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,857
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,430
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,857
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,430



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,857
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	18,563
TX_NEW_DSD	By Age/Sex: <1	143
TX_NEW_DSD	By Age/Sex: 1-9	818
TX_NEW_DSD	By Age/Sex: 10-14 Male	130
TX_NEW_DSD	By Age/Sex: 15-19 Male	2,645
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,254
TX_NEW_DSD	By Age/Sex: 50+ Male	1,229
TX_NEW_DSD	By Age/Sex: 10-14 Female	211
TX_NEW_DSD	By Age/Sex: 15-19 Female	2,919
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,456
TX_NEW_DSD	By Age/Sex: 50+ Female	1,608
TX_NEW_DSD	Sum of Age/Sex disaggregates	13,452
TX_NEW_DSD	Pregnancy status	2,539
TX_NEW_DSD	Breastfeeding status	236
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	932
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	932
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	865
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	750



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	58,132
TX_PVLS_DSD	Denominator: Indication: Routine	58,132
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,598
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,886
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,572
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	41,076
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	19,375
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	20,385
TX_RET_DSD	Numerator by Status: Pregnant	307
TX_RET_DSD	Numerator by Status: Breastfeeding	1,491
TX_RET_DSD	Denominator by Status: Pregnant	306
TX_RET_DSD	Denominator by Status: Breastfeeding	1,633
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	516
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,402
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	612
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,845



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	557
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,768
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	626
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,434
HTS_SELF_DSD	HTS_SELF_N_DSD	814
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	273
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	222
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	124
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	26
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	814
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted -	814

	Sex Partner	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	8,580
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	30,559
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,100
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	936
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	12,779
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	15,746
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	310
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	263
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,588
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	4,421
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	30,559
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	8,580
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	63,701
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,650
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,315
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	26,077
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	32,659
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	153
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	35



	Specimen Sent]: Other (No Xpert)	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	111
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	7
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	59,916
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	94
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	3,678
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	136

Implementing Mechanism Details

Mechanism ID: 18290	Mechanism Name: STRONG 1 - IRC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Rescue Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,696,090	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,696,090	
Funding Source	Funding Amount
GHP-State	3,696,090

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	1,589,323
---	-----------



Budget Code Information

Mechanism ID: 18290		
Mechanism Name: STRONG 1 - IRC		
Prime Partner Name: International Rescue Committee		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	514,749
Strategic Area	Budget Code	Planned Amount
Care	HKID	2,209,556
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	203,313
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	465,546
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	302,926
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,538



PP_PREV_DSD	Age/sex: 15-19 Male	748
PP_PREV_DSD	Age/sex: 20-24 Male	1,566
PP_PREV_DSD	Age/sex: 50+ Male	620
PP_PREV_DSD	Age/sex: 10-14 Female	2
PP_PREV_DSD	Age/sex: 15-19 Female	1,227
PP_PREV_DSD	Age/sex: 20-24 Female	2,509
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,672
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	1,728
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,861
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	877
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,768
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	572
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,583
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	501
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,976
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,477
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	941
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	869
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	53



	15-19, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	815
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	751
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	505
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	355
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	78
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	404
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	439
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	236
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	1,178
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19,	29



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,092
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,025
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	947
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	632
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	439
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	344
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	1,807
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	260
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	242
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	225
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	210
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	139
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	96
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	56



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	285
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	285
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	278
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	230
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	2

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	355



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	355
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	348
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	286
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	6
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	38,059
OVC_SERV_DSD	Age/Sex: 10-14 Male	3,775
OVC_SERV_DSD	Age/Sex: 15-17 Male	3,775
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,284
OVC_SERV_DSD	By: Age/sex: Male 25+	2,995
OVC_SERV_DSD	Age/Sex: 10-14 Female	7,111



OVC_SERV_DSD	Age/Sex: 15-17 Female	4,583
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,276
OVC_SERV_DSD	By: Age/sex: 25+ Female	4,494
OVC_SERV_DSD	Sum of Age/Sex disaggregates	19,244
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	548
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	284
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	189
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	730
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	379
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	252
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	730
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	379
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	252
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	182
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	95
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	63
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	182
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	95
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	63



OVC_SERV_DSD	Age/Sex: <1	1,511
OVC_SERV_DSD	Age/Sex: 1-9	6,255
OVC_SERV_DSD	Program Completion: Active	34,253
OVC_SERV_DSD	Program Completion: Graduation	3,806
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Economic Strengthening	36
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Education Support	110
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Other Service Areas	36
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Parenting/Caregiver Programs	146
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	146
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	27,010
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	38,059
HTS_SELF_DSD	HTS_SELF_N_DSD	1,730
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,184
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	136
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	95
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	95
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	107
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,730



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	1,730
--------------	---	-------

Implementing Mechanism Details

Mechanism ID: 18291	Mechanism Name: STRONG 2 - JHPIEGO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,313,023	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,313,023	
Funding Source	Funding Amount
GHP-State	4,313,023

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	1,817,703
---	-----------

Budget Code Information

Mechanism ID: 18291		
Mechanism Name: STRONG 2 - JHPIEGO		
Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	462,392
Strategic Area	Budget Code	Planned Amount



Care	HKID	2,378,091
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	487,334
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	402,394
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	582,812



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	35,214
PP_PREV_DSD	Age/sex: 15-19 Male	1,478
PP_PREV_DSD	Age/sex: 20-24 Male	3,140
PP_PREV_DSD	Age/sex: 50+ Male	1,232
PP_PREV_DSD	Age/sex: 10-14 Female	4
PP_PREV_DSD	Age/sex: 15-19 Female	2,466
PP_PREV_DSD	Age/sex: 20-24 Female	5,103
PP_PREV_DSD	Sum of Age/Sex disaggregates	13,423
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	3,463
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3,680
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,761



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,541
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,123
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	3,175
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,106
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	3,942
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,963
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	89
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	291
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	258
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	240
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	216
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	162



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	129
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	69
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	362
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	394
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	218
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	538
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	469
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	439
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	387
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	10



HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	304
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	246
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	305
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	1,611
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	91
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	78
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	72
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	66



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	97
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	85

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	31



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	177
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	177
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	158
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	3
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	37,576
OVC_SERV_DSD	Age/Sex: 10-14 Male	3,610
OVC_SERV_DSD	Age/Sex: 15-17 Male	3,610
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,200
OVC_SERV_DSD	By: Age/sex: Male 25+	2,802
OVC_SERV_DSD	Age/Sex: 10-14 Female	7,509
OVC_SERV_DSD	Age/Sex: 15-17 Female	4,749
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,332
OVC_SERV_DSD	By: Age/sex: 25+ Female	4,200
OVC_SERV_DSD	Sum of Age/Sex disaggregates	19,478



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	801
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	416
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	277
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,068
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	554
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	369
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,068
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	554
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	369
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	267
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	139
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	92
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	267
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	139
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	92
OVC_SERV_DSD	Age/Sex: <1	1,443
OVC_SERV_DSD	Age/Sex: 1-9	6,121
OVC_SERV_DSD	Program Completion: Active	33,818
OVC_SERV_DSD	Program Completion: Graduation	3,758



OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Economic Strengthening	53
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Education Support	160
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Other Service Areas	53
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Parenting/Caregiver Programs	214
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	214
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	27,044
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	37,576
HTS_SELF_DSD	HTS_SELF_N_DSD	605
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	399
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	605
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	605



Implementing Mechanism Details

Mechanism ID: 18292	Mechanism Name: STRONG 3 - SEVCI
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Sante Espoir Vie - Cote d'Ivoire	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,952,027	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,952,027	
Funding Source	Funding Amount
GHP-State	2,952,027

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	754,296
---	---------

Budget Code Information

Mechanism ID: 18292		
Mechanism Name: STRONG 3 - SEVCI		
Prime Partner Name: Sante Espoir Vie - Cote d'Ivoire		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	486,176
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,640,023
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	128,700
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	426,178
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	270,950
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	30,838
PP_PREV_DSD	Age/sex: 15-19 Male	1,474
PP_PREV_DSD	Age/sex: 20-24 Male	2,772
PP_PREV_DSD	Age/sex: 50+ Male	1,206
PP_PREV_DSD	Age/sex: 10-14 Female	1
PP_PREV_DSD	Age/sex: 15-19 Female	2,159
PP_PREV_DSD	Age/sex: 20-24 Female	4,188
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,800
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	3,073
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3,602
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,570
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,160
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,205
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,798



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	326
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	3,304
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,470
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	190
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	125
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,443
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,251
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	53
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,168
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,026
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	817
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	671



	50+, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	123
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	714
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	854
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	560
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	1,577
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,350
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,257
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	1,096
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	27



	Positive	
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	902
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	758
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	550
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	3,190
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	341
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	292
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	272
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	46



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	237
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	195
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	163
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	192
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	477



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	422
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	391
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	20



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	529
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	529
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	93



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	463
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	438
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	12
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	36,522
OVC_SERV_DSD	Age/Sex: 10-14 Male	3,836
OVC_SERV_DSD	Age/Sex: 15-17 Male	3,835
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,313
OVC_SERV_DSD	By: Age/sex: Male 25+	3,069
OVC_SERV_DSD	Age/Sex: 10-14 Female	6,136
OVC_SERV_DSD	Age/Sex: 15-17 Female	4,089
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,972
OVC_SERV_DSD	By: Age/sex: 25+ Female	4,602
OVC_SERV_DSD	Sum of Age/Sex disaggregates	17,896
OVC_SERV_DSD	Age/Sex: <1	1,533
OVC_SERV_DSD	Age/Sex: 1-9	6,137
OVC_SERV_DSD	Program Completion: Active	32,870
OVC_SERV_DSD	Program Completion: Graduation	3,652
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	25,566



OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	36,522
HTS_SELF_DSD	HTS_SELF_N_DSD	3,388
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2,197
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	300
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	243
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	209
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	208
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	231
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	3,388
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	3,387

Implementing Mechanism Details

Mechanism ID: 18293	Mechanism Name: STRONG 4 - EGPAF KenyaDougou
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,875,243	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,875,243	
Funding Source	Funding Amount



GHP-State	4,875,243
-----------	-----------

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	1,784,446
---	-----------

Budget Code Information

Mechanism ID: 18293		
Mechanism Name: STRONG 4 - EGPAF KenyaDougou		
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	487,773
Strategic Area	Budget Code	Planned Amount
Care	HKID	2,931,541
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	383,060
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	427,773
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	645,096
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	27,536
PP_PREV_DSD	Age/sex: 15-19 Male	1,196
PP_PREV_DSD	Age/sex: 20-24 Male	2,459
PP_PREV_DSD	Age/sex: 50+ Male	983
PP_PREV_DSD	Age/sex: 10-14 Female	1
PP_PREV_DSD	Age/sex: 15-19 Female	1,928
PP_PREV_DSD	Age/sex: 20-24 Female	3,881
PP_PREV_DSD	Sum of Age/Sex disaggregates	10,448
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,719
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,974
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,376
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	2,784
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	922
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,487
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	700
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	3,126
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,560
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	62
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	368



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	328
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	305
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	275
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	205
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	159
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	45
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	250
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	279
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	164



HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	532
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	473
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	441
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	394
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	294
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	232
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	206
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	1,114
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	9



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	96
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	90
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	58
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	67
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	18



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	6

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	170



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	64,979
OVC_SERV_DSD	Age/Sex: 10-14 Male	6,466
OVC_SERV_DSD	Age/Sex: 15-17 Male	6,466
OVC_SERV_DSD	By: Age/sex: Male 18-24	2,223
OVC_SERV_DSD	By: Age/sex: Male 25+	5,183
OVC_SERV_DSD	Age/Sex: 10-14 Female	11,971
OVC_SERV_DSD	Age/Sex: 15-17 Female	7,738
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,900
OVC_SERV_DSD	By: Age/sex: 25+ Female	7,775
OVC_SERV_DSD	Sum of Age/Sex disaggregates	32,641
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	584



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	303
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	202
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	779
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	404
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	269
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	779
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	404
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	269
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	195
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	101
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	67
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	195
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	101
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	67
OVC_SERV_DSD	Age/Sex: <1	2,586
OVC_SERV_DSD	Age/Sex: 1-9	10,671
OVC_SERV_DSD	Program Completion: Active	58,481
OVC_SERV_DSD	Program Completion: Graduation	6,498
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Economic Strengthening	39



OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Education Support	117
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Other Service Areas	39
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Parenting/Caregiver Programs	156
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	156
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	45,896
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	64,979
HTS_SELF_DSD	HTS_SELF_N_DSD	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	405
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	47
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	39
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	601

Implementing Mechanism Details

Mechanism ID: 18294	Mechanism Name: IPCI - Follow-on - Pasteur Institute of Cote d'Ivoire
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pasteur Institute of Ivory Coast	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 868,482	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 868,482	
Funding Source	Funding Amount
GHP-State	868,482

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18294		
Mechanism Name: IPCI - Follow-on - Pasteur Institute of Cote d'Ivoire		
Prime Partner Name: Pasteur Institute of Ivory Coast		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	311,682
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	130,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	426,800
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18295	Mechanism Name: Ministry of Health - Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Public Hygiene, Cote d'Ivoire	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 3,044,739	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,044,739	
Funding Source	Funding Amount
GHP-State	3,044,739

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18295		
Mechanism Name: Ministry of Health - Follow-on		
Prime Partner Name: Ministry of Health and Public Hygiene, Cote d'Ivoire		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	710,401
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	380,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	500,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	500,506
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	953,832
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18296	Mechanism Name: MPFFPE/PNOEV - Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Family, Women, and Social Affairs, Cote d'Ivoire	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,230,479	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,230,479	
Funding Source	Funding Amount
GHP-State	2,230,479

Cross-Cutting Budget Attribution(s)

Economic Strengthening	377,095
Adolescent Girls and Young Women (AGYW)	657,822

Budget Code Information

Mechanism ID: 18296		
Mechanism Name: MPFFPE/PNOEV - Follow-on		
Prime Partner Name: Ministry of Family, Women, and Social Affairs, Cote d'Ivoire		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	2,230,479
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	41,600
OVC_SERV_TA	Age/Sex: 10-14 Male	4,369
OVC_SERV_TA	Age/Sex: 15-17 Male	4,175
OVC_SERV_TA	By age/sex: 18-24 Male	1,440
OVC_SERV_TA	By age/sex: 25+ Male	3,541
OVC_SERV_TA	Age/Sex: 10-14 Female	6,944
OVC_SERV_TA	Age/Sex: 15-17 Female	4,543
OVC_SERV_TA	By age/sex: 18-24 Female	2,195
OVC_SERV_TA	By age/sex: 25+ Female	5,246
OVC_SERV_TA	Sum of Age/Sex disaggregates	20,031
OVC_SERV_TA	Age/Sex: <1	1,657
OVC_SERV_TA	Age/Sex: 1-9	7,490
OVC_SERV_TA	Program Completion: Active	37,439
OVC_SERV_TA	Program Completion: Graduated	4,161
OVC_HIVSTAT_TA	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	29,178



OVC_HIVSTAT_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	41,600
----------------	---	--------

Implementing Mechanism Details

Mechanism ID: 18377	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18378	Mechanism Name: Global Health Supply Chain-Procurement and Supply Management (GHSC-PSM, TO1),
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18378
---------------	-------



Mechanism Name: Global Health Supply Chain-Procurement and Supply Prime Partner Name: Management (GHSC-PSM, TO1), Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18382	Mechanism Name: GHSCTA - Global Health Supply Chain Technical Assistance
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18382		
Mechanism Name: GHSCTA - Global Health Supply Chain Technical Assistance		
Prime Partner Name: Chemonics International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18423	Mechanism Name: Global Health Supply Chain - Rapid Test Kits
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18423



Mechanism Name: Global Health Supply Chain - Rapid Test Kits Prime Partner Name: Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18431	Mechanism Name: CDC UNAIDS Central Mechanism
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS II	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 571,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 571,000	
Funding Source	Funding Amount
GHP-State	571,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18431		
Mechanism Name: CDC UNAIDS Central Mechanism		
Prime Partner Name: UNAIDS II		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	571,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18435	Mechanism Name: UCSF SI/M&E/Surveillance TA - Central mechanism
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18435



Mechanism Name: UCSF SI/M&E/Surveillance TA - Central mechanism		
Prime Partner Name: University of California at San Francisco		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18595	Mechanism Name: SEVCI New 2018
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Sante Espoir Vie - Cote d'Ivoire	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 5,432,160	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,432,160	
Funding Source	Funding Amount
GHP-State	5,432,160

Cross-Cutting Budget Attribution(s)

Gender: GBV	298,842
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	32,625

Budget Code Information

Mechanism ID:	18595	
Mechanism Name:	SEVCI New 2018	
Prime Partner Name:	Sante Espoir Vie - Cote d'Ivoire	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	302,626
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	288,414
Strategic Area	Budget Code	Planned Amount
Care	PDCS	404,503
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	471,514
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	424,028
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,128,413
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	412,662

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,384
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	117,527
PMTCT_ART_DSD	New on ART	1,128
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,256
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	117,527
PMTCT_STAT_DSD	Number of new ANC and L&D clients	124,576
PMTCT_STAT_DSD	By Age (Denominator): 10-14	351
PMTCT_STAT_DSD	By Age (Denominator): <15-19	17,843



PMTCT_STAT_DSD	By Age (Denominator): 20-24	30,976
PMTCT_STAT_DSD	By Age (Denominator): 50+	80
PMTCT_STAT_DSD	By Number of known positives: 15-19	20
PMTCT_STAT_DSD	By Number of known positives: 20-24	140
PMTCT_STAT_DSD	By Number of known positives: 50+	3
PMTCT_STAT_DSD	By Number of new positives: 15-19	64
PMTCT_STAT_DSD	By Number of new positives: 20-24	227
PMTCT_STAT_DSD	By Number of new negative: 10-14	357
PMTCT_STAT_DSD	By Number of new negative: 15-19	16,886
PMTCT_STAT_DSD	By Number of new negative: 20-24	29,079
PMTCT_STAT_DSD	By Number of new negative: 50+	73
PMTCT_STAT_DSD	By Age (Numerator): 10-14	355
PMTCT_STAT_DSD	By Age (Numerator): 15-19	16,889
PMTCT_STAT_DSD	By Age (Numerator): 20-24	29,131
PMTCT_STAT_DSD	By Age (Numerator): 50+	94
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	32,740
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	22,807
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	14,768
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	5,011
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	371
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	29,571
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	350
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	407
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	20,909
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	278
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	288



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	13,624
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	167
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	82
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	4,589
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	42
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	30,916
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	21,472
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	13,985
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	4,685
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	253,133
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,058
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	601
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,612
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	176
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,419
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24,	1,297



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	141
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,177
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	129
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	909
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	761
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	784
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	4,256
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	178
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,458
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3,100
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	8,178
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	496
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	7,127
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	436



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	6,522
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	397
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,879
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	361
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	4,635
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	274
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,924
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	229
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	4,038
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	21,939
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	222
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	78



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	194
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	266
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	149
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,076
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	337
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	952
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	296
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	870
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	270



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	797
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	248
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	609
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	190
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	505
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	196
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,063
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	258
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	357
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	16,886
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	29,079
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	227
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	142
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	1,548
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	130
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male,	1,364



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	122
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	583
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	1,220
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	1,122
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	515
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	515
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	4



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	456
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	431
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	874
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	731
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	361
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	361



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	296
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	541
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	541
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	59



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	479
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	3,617
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	251
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,757
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,757



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	2,424
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	136
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,280
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	126
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	30,376
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	350
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	20,909
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	278
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	13,624
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,589
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	39



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	896
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	790
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	720
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	656
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	305
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	305
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	265
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	10



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	242
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	508
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	421
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	6



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	153
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	97
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	200
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	13
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,932
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,984
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	44
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,111
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	48
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	729
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	45
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases,	1,174



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	45
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	720
GEND_GBV_DSD	Number of people receiving post-GBV care	230
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	36
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	194
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	150
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	5
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	54
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	6
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	51
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	6
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	11
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	7

	30-34, Female, Sexual Violence (Post-Rape Care)	
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	276
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	132
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	140
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,323
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,855
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	468
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,323



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	45,203
TX_CURR_DSD	Age/Sex: 15-19 Male	3,323
TX_CURR_DSD	Age/Sex: 15-19 Female	4,384
TX_CURR_DSD	Sum of age/sex disaggregates	7,707
TX_CURR_DSD	Age/Sex: <1	306
TX_CURR_DSD	Age/Sex: <1-9	2,272
TX_CURR_DSD	Age/Sex: 10-14 Male	455
TX_CURR_DSD	Age/Sex: 10-14 Female	622
TX_CURR_DSD	Age/Sex: 20-24 Male	2,910
TX_CURR_DSD	Age/Sex: 50+ Male	3,507
TX_CURR_DSD	Age/Sex: 20-24 Female	3,740
TX_CURR_DSD	Age/Sex: 50+ Female	4,572
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,909
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,075
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,909
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,075
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,497
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,075
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,497
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,075
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,691
TX_NEW_DSD	By Age/Sex: <1	167
TX_NEW_DSD	By Age/Sex: 1-9	907



TX_NEW_DSD	By Age/Sex: 10-14 Male	129
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,536
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,287
TX_NEW_DSD	By Age/Sex: 50+ Male	808
TX_NEW_DSD	By Age/Sex: 10-14 Female	220
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,741
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,396
TX_NEW_DSD	By Age/Sex: 50+ Female	976
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,093
TX_NEW_DSD	Pregnancy status	1,569
TX_NEW_DSD	Breastfeeding status	145
TX_NEW_DSD	FSW	23
TX_NEW_DSD	MSM	3
TX_NEW_DSD	People in prisons and other enclosed settings	11
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	94
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	583
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	94
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	583
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	94
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	511
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	94
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	471
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	43,754



TX_PVLS_DSD	Denominator: Indication: Routine	43,754
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,226
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,475
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,196
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	30,857
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,227
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,821
TX_RET_DSD	Numerator by Status: Pregnant	198
TX_RET_DSD	Numerator by Status: Breastfeeding	723
TX_RET_DSD	Denominator by Status: Pregnant	200
TX_RET_DSD	Denominator by Status: Breastfeeding	822
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	275
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,613
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	323
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,016
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	297

	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,821
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	339
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,364
HTS_SELF_DSD	HTS_SELF_N_DSD	782
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	168
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	278
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	212
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	104
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	782
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	782
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of	5,685



	Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	13,943
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	503
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	426
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,832
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	7,186
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	208
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	172
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,379
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,929
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	13,943
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,685
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	46,275
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,992
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,739
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	18,802
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	23,742
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	99
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	15
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	79



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	5
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	43,514
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	66
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,656
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	89

Implementing Mechanism Details

Mechanism ID: 18596	Mechanism Name: ACONDA New 2018
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: ACONDA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,723,710	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,723,710	
Funding Source	Funding Amount
GHP-State	6,723,710

Cross-Cutting Budget Attribution(s)

Gender: GBV	59,123
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Focus Area:	GBV Prevention
Sub Area:	Implementation



Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Collection and Use of Gender-related Strategic Information
Water	32,625

Budget Code Information

Mechanism ID: 18596		
Mechanism Name: ACONDA New 2018		
Prime Partner Name: ACONDA		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	393,717
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	321,272
Strategic Area	Budget Code	Planned Amount
Care	PDCS	451,783
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	419,926
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	295,616
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,325,963
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	515,433



Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,442
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	134,611
PMTCT_ART_DSD	New on ART	2,043
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,399
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	134,611
PMTCT_STAT_DSD	Number of new ANC and L&D clients	142,469
PMTCT_STAT_DSD	By Age (Denominator): 10-14	437
PMTCT_STAT_DSD	By Age (Denominator): <15-19	20,983
PMTCT_STAT_DSD	By Age (Denominator): 20-24	35,998
PMTCT_STAT_DSD	By Age (Denominator): 50+	106
PMTCT_STAT_DSD	By Number of known positives: 15-19	26
PMTCT_STAT_DSD	By Number of known positives: 20-24	150
PMTCT_STAT_DSD	By Number of known positives: 50+	2
PMTCT_STAT_DSD	By Number of new positives: 15-19	109
PMTCT_STAT_DSD	By Number of new positives: 20-24	400
PMTCT_STAT_DSD	By Number of new negative: 10-14	458
PMTCT_STAT_DSD	By Number of new negative: 15-19	19,741
PMTCT_STAT_DSD	By Number of new negative: 20-24	33,610
PMTCT_STAT_DSD	By Number of new negative: 50+	97
PMTCT_STAT_DSD	By Age (Numerator): 10-14	459
PMTCT_STAT_DSD	By Age (Numerator): 15-19	19,792
PMTCT_STAT_DSD	By Age (Numerator): 20-24	33,633



PMTCT_STAT_DSD	By Age (Numerator): 50+	101
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	37,785
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	25,538
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	16,461
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	5,161
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	432
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	34,091
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	640
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	453
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	23,256
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	508
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	311
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	15,133
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	315
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	92
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	4,718
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	35,861
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	24,191
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	15,704
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	4,870



PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,200
PrEP_NEW_DSD	Male 15-19	176
PrEP_NEW_DSD	Male 20-24	154
PrEP_NEW_DSD	Male 50+	176
PrEP_NEW_DSD	Female 15-19	242
PrEP_NEW_DSD	Female 20-24	198
PrEP_NEW_DSD	Female 50+	242
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	154
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	110
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	154
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	110
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	132
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	110
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	132
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	110
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	363,442
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,307
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	743
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,397
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	382
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male,	3,134



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	354
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,850
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	327
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,700
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	306
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,849
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	208
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,425
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	153
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	968
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	5,275
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	220
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	6,745
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3,821
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	14,239
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,083



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	13,237
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1,006
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	11,991
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	921
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	11,470
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	873
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	7,712
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	580
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,910
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	431
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	4,990
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	27,202
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	278
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male,	31



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	95
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	135
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	169
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	213
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	316
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	326
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male,	184



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,344
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	739
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2,180
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	687
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,987
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	630
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,891
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	595
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,268
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	396
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	951
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	295
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	242
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,318
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	328
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	458
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	19,741
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	109



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	33,610
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	400
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	97
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	137
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	3,380
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	253
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	3,142
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	236
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	769
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	2,890
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	214
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	2,725
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	206
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	19



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	1,046
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	1,046
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	1,003
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	849
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	1,813
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	126
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male,	1,342



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	736
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	231
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	736
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	231
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	699
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	597
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	185



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,081
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,081
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,011
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	880
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown	4,471

	Sex, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	312
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	844
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,518
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	333
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	844
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,518
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	333
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	844
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,248
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	316
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	844
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,667
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	267



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	34,848
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	640
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	23,256
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	508
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	15,133
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	315
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,718
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	1,967
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	1,831
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,682
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	1,587
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	108



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	606
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	606
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	581
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	489
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	1,058
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female,	66



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	136
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	264
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	328



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	65
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,631
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,903
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	86
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,051
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	86
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,408
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	83
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,307
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	86
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,427
GEND_GBV_DSD	Number of people receiving post-GBV care	278
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	26



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	252
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	219
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	37
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	64
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	74
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	8
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	8
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	1,077

	during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	502
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	19
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	542
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,329
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,661
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	668
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,329
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	77,634
TX_CURR_DSD	Age/Sex: 15-19 Male	5,809
TX_CURR_DSD	Age/Sex: 15-19 Female	7,794
TX_CURR_DSD	Sum of age/sex disaggregates	13,603
TX_CURR_DSD	Age/Sex: <1	419
TX_CURR_DSD	Age/Sex: <1-9	3,137
TX_CURR_DSD	Age/Sex: 10-14 Male	633
TX_CURR_DSD	Age/Sex: 10-14 Female	847
TX_CURR_DSD	Age/Sex: 20-24 Male	5,081



TX_CURR_DSD	Age/Sex: 50+ Male	6,001
TX_CURR_DSD	Age/Sex: 20-24 Female	6,530
TX_CURR_DSD	Age/Sex: 50+ Female	7,985
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	5,078
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,631
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	5,078
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,631
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,359
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,631
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	4,359
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,631
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	24,226
TX_NEW_DSD	By Age/Sex: <1	245
TX_NEW_DSD	By Age/Sex: 1-9	1,357
TX_NEW_DSD	By Age/Sex: 10-14 Male	201
TX_NEW_DSD	By Age/Sex: 15-19 Male	3,454
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,983
TX_NEW_DSD	By Age/Sex: 50+ Male	1,498
TX_NEW_DSD	By Age/Sex: 10-14 Female	341
TX_NEW_DSD	By Age/Sex: 15-19 Female	3,720
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,172
TX_NEW_DSD	By Age/Sex: 50+ Female	2,015
TX_NEW_DSD	Sum of Age/Sex disaggregates	17,384
TX_NEW_DSD	Pregnancy status	3,306



TX_NEW_DSD	Breastfeeding status	294
TX_NEW_DSD	FSW	221
TX_NEW_DSD	MSM	169
TX_NEW_DSD	People in prisons and other enclosed settings	6
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	215
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	215
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	215
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,105
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	215
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	940
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	73,321
TX_PVLS_DSD	Denominator: Indication: Routine	73,321
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,183
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	17,693
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,101
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	51,344
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	20,518



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	21,623
TX_RET_DSD	Numerator by Status: Pregnant	379
TX_RET_DSD	Numerator by Status: Breastfeeding	1,246
TX_RET_DSD	Denominator by Status: Pregnant	392
TX_RET_DSD	Denominator by Status: Breastfeeding	1,442
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	524
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,795
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	622
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,577
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	563
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,182
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	639



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,239
HTS_SELF_DSD	HTS_SELF_N_DSD	1,467
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	292
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	475
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	388
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	243
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	53
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,467
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,467
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	16,326
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	50,351
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,846
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,574



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	21,012
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	25,915
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	598
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	511
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	6,813
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	8,403
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	50,351
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	16,326
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	80,078
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,303
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,867
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	32,701
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	41,207
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	185
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	53
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	122
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	10
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	75,464
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	132
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	4,458
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	178



Implementing Mechanism Details

Mechanism ID: 18597	Mechanism Name: Fondation ARIEL New 2018
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Fondation Ariel Glaser Pour la Lutte Contre le Sida Pediatrique en Cote D'Ivoire	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 8,524,005	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,524,005	
Funding Source	Funding Amount
GHP-State	8,524,005

Cross-Cutting Budget Attribution(s)

Gender: GBV	399,612
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	32,625



Budget Code Information

Mechanism ID:	18597	
Mechanism Name:	Fondation ARIEL New 2018	
Prime Partner Name:	Fondation Ariel Glaser Pour la Lutte Contre le Sida Pediatrique en Cote D'Ivoire	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	298,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	541,794
Strategic Area	Budget Code	Planned Amount
Care	PDCS	438,024
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,164,112
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	380,312
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,135,626
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	566,137

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	1,957



	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	89,451
PMTCT_ART_DSD	New on ART	896
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,061
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	89,451
PMTCT_STAT_DSD	Number of new ANC and L&D clients	94,123
PMTCT_STAT_DSD	By Age (Denominator): 10-14	262
PMTCT_STAT_DSD	By Age (Denominator): <15-19	14,004
PMTCT_STAT_DSD	By Age (Denominator): 20-24	24,400
PMTCT_STAT_DSD	By Age (Denominator): 50+	160
PMTCT_STAT_DSD	By Number of known positives: 15-19	15
PMTCT_STAT_DSD	By Number of known positives: 20-24	122
PMTCT_STAT_DSD	By Number of new positives: 15-19	49
PMTCT_STAT_DSD	By Number of new positives: 20-24	181
PMTCT_STAT_DSD	By Number of new negative: 10-14	248
PMTCT_STAT_DSD	By Number of new negative: 15-19	13,265
PMTCT_STAT_DSD	By Number of new negative: 20-24	22,882
PMTCT_STAT_DSD	By Number of new negative: 50+	145
PMTCT_STAT_DSD	By Age (Numerator): 10-14	253
PMTCT_STAT_DSD	By Age (Numerator): 15-19	13,339
PMTCT_STAT_DSD	By Age (Numerator): 20-24	23,193
PMTCT_STAT_DSD	By Age (Numerator): 50+	153
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	25,434
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	16,780
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	9,935
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	3,148
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	320



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	23,554
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	295
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	353
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	15,280
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	235
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	235
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	9,179
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	118
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	61
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,896
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	24,147
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	15,853
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	9,529
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,984
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,456
PrEP_NEW_DSD	Male 15-19	116
PrEP_NEW_DSD	Male 20-24	102
PrEP_NEW_DSD	Male 50+	116
PrEP_NEW_DSD	Female 15-19	160
PrEP_NEW_DSD	Female 20-24	132



PrEP_NEW_DSD	Female 50+	160
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	102
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	74
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	102
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	74
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	88
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	74
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	88
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	74
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	519,109
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,438
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	103
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,530
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	5,393
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	564
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	4,770
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	493
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	4,428
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	459
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	3,985



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	408
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	3,013
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	318
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,401
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	257
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1,655
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	9,348
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	390
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	12,560
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	127
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	7,876
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	33,680
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,573
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	29,705
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1,377
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	27,545
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,273



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	24,737
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,147
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	18,868
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	882
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	15,150
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	717
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	8,538
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	48,214
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	487
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	111
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	102



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	136
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	184
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	223
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	339
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	72
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	608
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	148
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	376
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3,202
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1,049
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2,811
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	923



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,606
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	864
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,340
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	766
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,791
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	597
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,464
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	491
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	415
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2,328
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	583
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	248
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	13,265
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	22,882
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	181
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	237
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	351
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14,	4



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	4,996
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	367
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	4,375
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	328
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	1,365
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	4,067
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	3,632
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	270
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	300
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	1,639
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34,	300



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	1,639
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	119
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	1,472
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	1,347
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	2,805
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	201
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	2,269
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	183
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	55



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,059
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	352
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,059
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	352
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	947
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	313
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	870
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	286
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29,	1,755



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	186
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,755
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	186
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,591
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	166
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,436
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	152
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	8,175
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	569
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,987
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	141



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	11,008
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	525
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,987
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	11,008
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	525
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,987
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	9,917
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	461
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,987
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	9,013
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	420
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	23,542
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	295
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	15,280



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	235
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	9,179
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	118
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,896
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	2,929
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	191
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	2,574
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	2,383
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	152
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	2,137
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	958
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	64



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	958
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	862
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	790
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	1,655
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1,334
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29,	145



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	261
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	281
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	267
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	39
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,974
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	4,011



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	99
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,354
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	107
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,414
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	97
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,400
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	107
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,407
GEND_GBV_DSD	Number of people receiving post-GBV care	53
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	50
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	45
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1



GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	1
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	1
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	1
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	981
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	447
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	505
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,911
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,528
PMTCT_EID_DSD	By infants who received their first virologic HIV test	383



	between 2 and 12 months of age	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,911
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	94,587
TX_CURR_DSD	Age/Sex: 15-19 Male	7,014
TX_CURR_DSD	Age/Sex: 15-19 Female	9,276
TX_CURR_DSD	Sum of age/sex disaggregates	16,290
TX_CURR_DSD	Age/Sex: <1	542
TX_CURR_DSD	Age/Sex: <1-9	4,052
TX_CURR_DSD	Age/Sex: 10-14 Male	808
TX_CURR_DSD	Age/Sex: 10-14 Female	1,089
TX_CURR_DSD	Age/Sex: 20-24 Male	6,168
TX_CURR_DSD	Age/Sex: 50+ Male	7,473
TX_CURR_DSD	Age/Sex: 20-24 Female	7,962
TX_CURR_DSD	Age/Sex: 50+ Female	9,676
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	6,172
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	4,398
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	6,172
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4,398
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	5,288
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4,398
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,288
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	4,398
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	32,865



TX_NEW_DSD	By Age/Sex: <1	335
TX_NEW_DSD	By Age/Sex: 1-9	1,910
TX_NEW_DSD	By Age/Sex: 10-14 Male	315
TX_NEW_DSD	By Age/Sex: 15-19 Male	4,415
TX_NEW_DSD	By Age/Sex: 20-24 Male	3,675
TX_NEW_DSD	By Age/Sex: 50+ Male	2,301
TX_NEW_DSD	By Age/Sex: 10-14 Female	494
TX_NEW_DSD	By Age/Sex: 15-19 Female	5,060
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,131
TX_NEW_DSD	By Age/Sex: 50+ Female	2,845
TX_NEW_DSD	Sum of Age/Sex disaggregates	23,236
TX_NEW_DSD	Pregnancy status	4,486
TX_NEW_DSD	Breastfeeding status	341
TX_NEW_DSD	FSW	9
TX_NEW_DSD	MSM	20
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	294
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,666
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	294
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,666
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	294
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,491
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	294
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,359
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	89,133



	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Denominator: Indication: Routine	89,133
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,332
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	21,183
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,335
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	63,285
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	22,771
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	23,974
TX_RET_DSD	Numerator by Status: Pregnant	368
TX_RET_DSD	Numerator by Status: Breastfeeding	1,802
TX_RET_DSD	Denominator by Status: Pregnant	357
TX_RET_DSD	Denominator by Status: Breastfeeding	1,972
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	371
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,263
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	423
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,713
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	401



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,719
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	439
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,413
HTS_SELF_DSD	HTS_SELF_N_DSD	836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	286
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	224
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	119
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	836
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	836
TB_PREV_DSD	The number of ART patients who completed a course	20,418



	of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	69,500
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,819
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2,473
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	28,659
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	35,547
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	774
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	672
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8,494
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	10,478
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	69,500
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	20,418
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	99,985
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,180
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,690
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	40,992
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	51,118
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	248
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	44
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	194



	Specimen Sent]: Smear Only	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	10
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	93,825
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	144
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	5,940
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	204

Implementing Mechanism Details

Mechanism ID: 18606	Mechanism Name: Breakthrough Action
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,333,538	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,333,538	
Funding Source	Funding Amount
GHP-State	3,333,538

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18606		
Mechanism Name: Breakthrough Action		
Prime Partner Name: Johns Hopkins University Center for Communication Programs		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	59,980
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	59,980
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	328,278
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,703,570
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	698,459
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	483,271
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	74,490
PP_PREV_DSD	Age/sex: 15-19 Male	3,402
PP_PREV_DSD	Age/sex: 20-24 Male	6,670
PP_PREV_DSD	Age/sex: 50+ Male	2,744



PP_PREV_DSD	Age/sex: 10-14 Female	4
PP_PREV_DSD	Age/sex: 15-19 Female	5,215
PP_PREV_DSD	Age/sex: 20-24 Female	10,073
PP_PREV_DSD	Sum of Age/Sex disaggregates	28,108
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	7,384
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	8,422
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	3,723
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	7,576
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	2,659
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	6,747
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,254
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	8,617
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	22,893
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	129
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	74
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,136
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,024
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	956



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	867
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	624
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	470
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	98
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	521
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	581
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	332
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	1,544
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,390



HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,302
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	1,179
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	845
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	635
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	433
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	2,326
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	277
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	39



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	249
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	233
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	210
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	152
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	114
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	28
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	140
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	358
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29,	15



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	358
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	336
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	290
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	11



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	483
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	483
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	91



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	453
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	392
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	8
HTS_SELF_DSD	HTS_SELF_N_DSD	4,259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2,856
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	352
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	285
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	249
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	278
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	4,259
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	4,156
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	103



Implementing Mechanism Details

Mechanism ID: 18607	Mechanism Name: Leadership, Management, Governance (LMG) follow on
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: MSH/Leadership Management & Sustainability (LMS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18607	
Mechanism Name:	Leadership, Management, Governance (LMG) follow on	
Prime Partner Name:	MSH/Leadership Management & Sustainability (LMS)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18610	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18639	Mechanism Name: Health Workforce 21
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 150,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	



Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18639 Mechanism Name: Health Workforce 21 Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	41,250
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	7,500
Strategic Area	Budget Code	Planned Amount
Care	PDCS	15,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	5,250
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	77,250
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	3,750



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70038	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70057	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70058	Mechanism Name: FANTA Follow On
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70058 Mechanism Name: FANTA Follow On Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70059	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 70060	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70061	Mechanism Name: [Placeholder - 70061 Cote d'Ivoire USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70061		
Mechanism Name: [Placeholder - 70061 Cote d'Ivoire USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70062	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70503	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	35,600	35,600
ICASS		0		0	1,000,000	1,000,000
Institutional Contractors				0	250,000	250,000
Management Meetings/Professional Development		0		0	168,400	168,400
Non-ICASS Administrative Costs		0		0	35,000	35,000
Staff Program Travel		0		0	115,000	115,000
USG Staff Salaries and Benefits - Internationally Recruited		915,112		915,112	900,000	1,815,112
USG Staff Salaries and Benefits - Locally Recruited		757,818		757,818	196,000	953,818



Total	0	1,672,930	0	1,672,930	2,700,000	4,372,930
--------------	----------	------------------	----------	------------------	------------------	------------------

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		0		0	40,000	40,000
Staff Program Travel				0	60,000	60,000
USG Staff Salaries and Benefits - Locally Recruited				0	160,000	160,000
Total	0	0	0	0	260,000	260,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		1,200,000		1,200,000	0	1,200,000
Computers/IT Services		390,000		390,000	0	390,000



ICASS	1,100,000	891,763		1,991,763	0	1,991,763
Institutional Contractors		660,000		660,000	0	660,000
Management Meetings/Professional Development		574,000		574,000	0	574,000
Non-ICASS Administrative Costs	100,000	691,751		791,751	0	791,751
Staff Program Travel	375,000	223,060		598,060	0	598,060
USG Staff Salaries and Benefits - Internationally Recruited		983,523		983,523	0	983,523
USG Staff Salaries and Benefits - Locally Recruited	200,000	3,987,279		4,187,279	0	4,187,279
Total	1,775,000	9,601,376	0	11,376,376	0	11,376,376

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		94,381		94,381	0	94,381
Management		29,237		29,237	4,763	34,000

Approved



Meetings/Professional Development						
Non-ICASS Administrative Costs		28,210		28,210	14,290	42,500
Staff Program Travel		2,030		2,030	3,970	6,000
USG Staff Salaries and Benefits - Locally Recruited		181,683		181,683	56,366	238,049
Total	0	335,541	0	335,541	79,389	414,930